Introduction {#s1}
============

One of the most important functions in a cell is the accurate interpretation of the information encoded in extracellular signals leading to context-dependent control of cell fate. This is achieved via complex and dynamic signal transduction networks, through which gene expression is re-programmed in response to specific environmental cues ([@bib7]). Many signalling systems are subject to temporal changes, involving dynamic alterations to the states of their constituent genes and proteins, with time scales ranging from seconds (Calcium signalling \[[@bib9]; [@bib60]\]), to hours (DNA damage response \[[@bib37]\], inflammatory response \[[@bib5]\]), to days (circadian clock \[[@bib72]\], cell cycle \[[@bib59]\]). Although previous studies have indicated interactions between proteins associated with different dynamical systems ([@bib75]; [@bib11]; [@bib21]), how and when signalling systems are dynamically integrated to determine important cell fate decisions is not well understood.

Nuclear Factor kappa B (NF-κB) is an important signalling system, implicated in many diseases including autoimmune diseases and cancer ([@bib24]). Inflammatory cues such as Tumour Necrosis Factor alpha (TNFα) can trigger the nuclear translocation of the NF-κB RelA subunit and activation of target gene transcription ([@bib26]). Nuclear NF-κB activates feedback regulators, including the inhibitory kappa B alpha (IκBα) and epsilon (IκBε) inhibitors ([@bib4]; [@bib33]; [@bib52]), which bind and transport NF-κB back into the cytoplasm. In response to TNFα, this system shows nuclear-cytoplasmic (N:C) oscillations in the localization of the NF-κB complex associated with out-of-phase cycles of degradation and re-synthesis of IκB proteins ([@bib47]; [@bib5]; [@bib38]; [@bib65]; [@bib67]; [@bib70]; [@bib58]; [@bib31]). Through systems biology and experimental approaches, the frequency of these oscillations has been proposed to be a key parameter that regulates the pattern of downstream gene expression ([@bib5]; [@bib39]; [@bib76]).

NF-κB signalling has also been suggested to have a role in controlling cell division through a number of different mechanisms ([@bib54]). Many NF-κB family members have been characterised as oncoproteins (e.g. c-Rel and Bcl-3 \[[@bib26]\]). Also, a number of cell cycle control proteins have been shown to be NF-κB transcriptional targets, including Cyclin D, ([@bib25]; [@bib61]) and p21, an inhibitor of Cyclin Dependent Kinase (CDK) activity ([@bib28]).

Although interactions between NF-κB and the cell cycle have been reported ([@bib36]; [@bib55]; [@bib54]); observing the dynamics of such interactions is challenging via traditional biochemical techniques, which often fail to capture the heterogeneity in a cellular population. Analysis of cell-to-cell heterogeneity has revealed novel regulatory mechanisms for diverse cellular processes ([@bib53]) and it has been suggested that this is a fundamental property of the NF-κB response ([@bib52]).

The E2 Factor (E2F) proteins are differentially expressed during the cell cycle to control cell proliferation ([@bib10]). They are a family of transcription factors that play a key role in the G1/S cell cycle checkpoint. Previous studies have provided preliminary evidence for physical interaction between NF-κB and E2F proteins ([@bib66]; [@bib40]; [@bib23]) In the current study, a combination of single cell imaging and mathematical modelling was applied to investigate reciprocal co-ordination of the NF-κB response and cell proliferation driven by dynamic interactions between RelA and E2F proteins.

Results {#s2}
=======

The NF-κB response depends on the cell cycle phase {#s2-1}
--------------------------------------------------

We investigated the effect of cell cycle timing on the NF-κB response in HeLa cervical cancer and SK-N-AS neuroblastoma cells. SK-N-AS cells showed repeated oscillations in response to TNFα stimulation that were more damped than those seen in HeLa cells (see [Appendix 1---figure 1](#fig10){ref-type="fig"} for longer time course data \[[@bib47]; [@bib5]\]). In previous studies it was observed that when SK-N-AS cells were treated with a saturating dose of TNFα (10 ng/ml) the initial response of NF-κB (i.e. immediate RelA nuclear translocation) was relatively synchronous between cells ([@bib47]; [@bib5]; [@bib70]) ([Figure 1A](#fig1){ref-type="fig"}; [Appendix 1---figure 1](#fig10){ref-type="fig"}). However, these data showed a variation in timing and amplitude when cells were treated with a lower dose of 30 pg/ml TNFα, even though this was functionally close to a saturating dose that gave a strong population-level NF-κB response ([@bib70]) ([Figure 1B](#fig1){ref-type="fig"}). In common with treatment of SK-N-AS cells at 30 pg/ml, HeLa cells showed greater heterogeneity in their initial response at a saturating 10 ng/ml dose of TNFα, with some cells showing little or no response and others showing a variable delay ([@bib48]; [@bib47]) ([Figure 1C](#fig1){ref-type="fig"}). This is in agreement with data showing heterogeneity of the initial response in other cell types ([@bib67]; [@bib79]). HeLa cells showed no significant translocation in response to 30 pg/ml TNFα ([Figure 1D](#fig1){ref-type="fig"}), suggesting that these cell types have differential dynamic NF-κB responses at varying TNFα doses.10.7554/eLife.10473.003Figure 1.NF-κB dynamics following TNFα treatment in HeLa and SK-N-AS cells: Mapping the NF-κB response over the cell cycle in synchronized HeLa cells.(**A,B,C** and **D**) The dynamics of RelA-dsRedxp following 10 ng/ml TNFα treatment in transiently transfected SK-N-AS (**A**), or following 30 pg/ml TNFα treatment in SK-N-AS, and 10 ng/ml TNFα treatment in HeLa cells (**C**), and at 30 pg/ml for HeLa (**D**) cells (n=30 cells analysed per condition). (**E**) The localization of endogenous RelA in different cell cycle phases, observed by immunocytochemistry at 2 hr (G1/S transition), 4 hr (mid S-phase), post-release from double thymidine block and with 15 min TNFα treatment. (**F** and **G**) The dynamics of RelA-dsRedxp in transiently transfected HeLa cells synchronized by a double thymidine block, following 10 ng/ml TNFα treatment at G1/S (**F**), or passing through S-phase (**G**) (n=20 cells analysed per condition). (**H**) Western blot of Ser^536^phopho-RelA (p-RelA), IκBα, and cyclophilin-A (cyclo-A) levels in synchronized HeLa cells harvested at 1 hr time intervals over the G1/S transition following 15 min treatment with TNFα. Also shown are asynchronous, non-stimulated (ASY NST) and asynchronous, stimulated (ASY ST) controls, harvested at t=0.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.003](10.7554/eLife.10473.003)

We hypothesised that this cell-to-cell heterogeneity in response might be a consequence of cell cycle phase. To test this hypothesis, we investigated the role of cell cycle in both the HeLa and SK-N-AS cells, as these show different dynamic responses to TNFα that are typical of the profile of a wide range of cell lines ([@bib67]; [@bib70]; [@bib79]; [@bib31]). Initially, HeLa cells were treated with 10 ng/ml TNFα at various stages of the cell cycle ([Figure 1E--H](#fig1){ref-type="fig"}), as they could be easily synchronized at late G1 by a double thymidine block (see [Appendix 1---figure 2](#fig11){ref-type="fig"}). When endogenous RelA was examined using immunocytochemistry, HeLa cells treated with 10 ng/ml TNFα in S-phase displayed a reduced nuclear localization, compared to those treated in late G1 ([Figure 1E](#fig1){ref-type="fig"}). These results were confirmed using time-lapse imaging of synchronised HeLa cells transiently transfected with RelA-DsRedxp. Cells treated in late G1 showed a strong synchronous translocation of RelA, whereas cells treated in S-phase showed reduced RelA translocation ([Figure 1F,G)](#fig1){ref-type="fig"}. These cell cycle-dependent differences following TNFα treatment of synchronized cell populations were supported by alterations in the extent of IκBα degradation and RelA Serine^536^ phosphorylation at different stages of the cell cycle as measured by western blot ([Figure 1H](#fig1){ref-type="fig"}).

To further investigate the effect of cell cycle on the NF-κB response, unsynchronized populations of HeLa and SK-N-AS cells were followed by time-lapse imaging through successive cell divisions. 30 hr after the start of this time-course, HeLa cells were stimulated with 10 ng/ml TNFα. Cells were assigned to different cell cycle phases based upon their mitosis-to-mitosis and mitosis-to-treatment timings ([Figure 2A and B](#fig2){ref-type="fig"}).10.7554/eLife.10473.004Figure 2.Mapping the NF-κB response over the cell cycle through virtual synchronization.(**A**) Selected images from time-lapse imaging of RelA-dsRedxp transiently expressing Hela cells treated with 10 ng/ml TNFα. (**B**) Virtual synchronization of HeLa cells treated with 10 ng/ml TNFα. Cells were imaged through two successive divisions (M) allowing correlation of cell cycle timing of TNFα treatment (parameter 1) to RelA dynamics (parameters 2, 3 and 4) and cell cycle duration (parameters 1 plus 5). (**C**) Representative cells of RelA-dsRedxp dynamics following TNFα treatment in asynchronous cells, then virtually synchronized into G1 (n=115), G1/S (n=32), S (n=52) and G2 (n=38) phases.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.004](10.7554/eLife.10473.004)10.7554/eLife.10473.005Figure 2---figure supplement 1.Analysis of cell cycle duration and G1/S timing in HeLa and SK-N-AS cells.(**A**) Time series for FUCCI expression in single representative HeLa and SK-N-AS cells. White arrows mark cells before and after the fluorescence levels were detectable. (**B**) Analysis of cells in (**A**), showing the G1/S crossing point in fluorescence levels from reporters of SCF (SKP2) (Orange) and APC (Green) E3 ubiquitin ligase activity. (**C**) Analysis of the G1/S crossing point and cell cycle duration in populations of HeLa and SK-N-AS cells transfected with FUCCI vectors (n ≥ 30 cells for all conditions).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.005](10.7554/eLife.10473.005)10.7554/eLife.10473.006Figure 2---figure supplement 2.Statistical analysis of NF-κB translocation in HeLa cells at inferred cell cycle stages following 10 ng/ml TNFα stimulation.(**A**) Analysis of dynamics of initial RelA-dsRedxp translocation with respect to cell cycle phase, using virtual synchronization in HeLa cells. Data were analyzed using nonparametric Anova analysis with Dunn correction for multiple comparisons. Red lines indicate mean normalised amplitude of NF-κB nuclear translocation for different cell cycle phases, and the population average (dotted line). (**B**) Analysis of nuclear RelA occupancy assessed in non-synchronized cells expressing RelA-dsRedxp following treatment with 10 ng/ml TNFα. Statistical analysis showed significant difference between cell cycle phases with respect to distribution of amplitude of the response (Anova analysis with Dunn correction for multiple comparisons).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.006](10.7554/eLife.10473.006)10.7554/eLife.10473.007Figure 2---figure supplement 3.Statistical analysis of NF-κB translocation in SK-N-AS cells at inferred cell cycle stages following 30 pg/ml TNFα stimulation.(**A**) Correlation of estimated cell cycle timing with RelA-dsRedxp N:C peak amplitude following 30 pg/ml TNFα treatment (n=138). (**B**) Analysis of dynamics of initial RelA-dsRedxp translocation with respect to cell cycle phase. Statistical analysis showed a difference between G1 and S with respect to distribution of amplitude of the response (Anova analysis with Dunn correction for multiple comparisons).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.007](10.7554/eLife.10473.007)

To ensure the accuracy of the inferred cell cycle stage in these experiments, the cycle timing of cells at the point of TNFα treatment was calibrated through control experiments using Fluorescent Ubiquitin-based Cell Cycle Indicators (FUCCI) in both HeLa and SK-N-AS cells ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). The crossing point of Red and Green FUCCI reporters was determined, and defined as the G1/S checkpoint. The average and distribution of the cell cycle duration in populations of HeLa and SK-N-AS cells was also measured ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).

The resulting data suggested that HeLa cells treated with TNFα in late G1 (inferred to be G1/S) showed an increase in the translocation amplitude compared to the unsynchronized population average ([Figure 2C](#fig2){ref-type="fig"}). By contrast, cells treated in S-phase appeared to show a damped or delayed response ([Figure 2C](#fig2){ref-type="fig"}), with markedly reduced amplitude of nuclear NF-κB translocation. In G2 phase the NF-κB response appeared to be restored. Analysis of the complete data set confirmed that there was statistically significant higher nuclear translocation amplitude in HeLa cells at G1/S and significantly reduced amplitude in S-phase, compared to G1 and G2 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

A smaller data set from SK-N-AS cells treated with 30 pg/ml TNFα, showed once again a statistically reduced translocation in S-phase compared to G1-phase. Visually the data are consistent with increased translocation in late G1 and a restored level of translocation in G2- compared to S-phase. However more cells would be required for a statistical analysis of possible differences between these cell cycle phases. ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

The effect of NF-κB signalling on cell cycle timing {#s2-2}
---------------------------------------------------

We also measured the effect of TNFα treatment on HeLa cell cycle duration ([Figure 3](#fig3){ref-type="fig"}). It was found that mean cell cycle duration for cells treated with TNFα showed a small, but statistically significant increase of 1.9 hr (\~10%) compared to untreated cells, with the variability in the total population increasing by \~2-fold ([Figure 3](#fig3){ref-type="fig"}). Within this TNFα-treated population, cells treated in late G1 were more susceptible to cell cycle elongation with a cell cycle duration that was \~1/3 longer than the untreated population average. TNFα treatment in S-phase had no statistically significant effect on the timing of mitosis. These data suggest a potential direct or indirect role for the NF-κB system in controlling cell cycle duration through an unknown mechanism at the G1/S phase of the cell cycle.10.7554/eLife.10473.008Figure 3.Cell cycle length and variability is modified by TNFα addition at G1/S.Analysis of the timing and variability of mitosis (parameter 1 plus 5 from [Figure 2B](#fig2){ref-type="fig"}) following 10 ng/ml TNFα treatment of asynchronous untransfected HeLa cells, compared to subsets of those cells stimulated at late G1- or S-phase. Mean durations were analysed using nonparametric Anova analysis with Dunn correction for multiple comparisons. Variability in the data was analysed using Levene's test for equality of variance.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.008](10.7554/eLife.10473.008)

E2F-1 levels control the dynamics of the NF-κB response {#s2-3}
-------------------------------------------------------

The mechanism for alteration of NF-κB responses between the late G1- and S-phases of the cell cycle was sought. Previous studies had suggested that E2-Factor-1 (E2F-1) could physically associate with RelA, and/or its major dimer partner p50 ([@bib36]; [@bib66]; [@bib40]). E2F-1 is the key transcriptional regulator of the cell cycle transition between G1- and S-phase ([@bib69]), where its expression is highest. In the presence of ectopically-expressed EGFP-E2F-1, we observed a reduction in the activity of a NF-κB-regulated luciferase reporter ([Figure 4A](#fig4){ref-type="fig"}). Moreover, the ability of NF-κB to induce endogenous mRNA levels of IκBα and IκBε was impaired in cells co-expressing EGFP-E2F-1 and RelA-DsRedxp, compared to cells expressing RelA-DsRedxp alone ([Figure 4B](#fig4){ref-type="fig"}). E2F-1 target gene transcription was also impaired by RelA expression, as indicated by a reduction in the activity of a Cyclin E luciferase reporter ([Figure 4C](#fig4){ref-type="fig"}) and in the mRNA level of E2F-1 itself ([Figure 4D](#fig4){ref-type="fig"}). These data support the reciprocal and coordinated control of transcription by E2F-1 and NF-κB.10.7554/eLife.10473.009Figure 4.Physical and functional interaction between NF-κB and E2F-1 systems.(**A**) NF-κB-dependent transcription was assessed by luciferase reporter assay (NF-luc), in SK-N-AS cells (n=3, +/- s.d) expressing EGFP-E2F-1, RelA-dsRedxp or both. (**B**) IκBα and IκBε mRNA levels in SK-N-AS cells (n=3, +/- s.d) following transient expression of EGFP-E2F-1, RelA-DsRedxp or both. (**C**) E2F-1-dependent transcription as assessed by luciferase reporter assay (CyclinE-luc), in SK-N-AS cells (n=3, +/- s.d) expressing EGFP-E2F-1, RelA-dsRedxp or both. (**D**) E2F-1 mRNA levels in SK-N-AS cells (n=3, +/- s.d) transiently transfected with RelA-dsRedxp. (**E**) Representative SK-N-AS cells transiently expressing EGFP-E2F-1 (green), RelA-dsRedxp (red), both fluorescent fusion proteins at different levels, or EGFP-E2F-1, RelA-dsRedxp and IκBα-AmCyan (blue).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.009](10.7554/eLife.10473.009)10.7554/eLife.10473.010Figure 4---figure supplement 1.E2F-1 modulates NF-κB dynamics in the absence of stimulus in SK-N-AS cells.(**A**) Time-lapse confocal microscopy of representative SK-N-AS cells transiently transfected with RelA-dsRedxp and EGFP-E2F-1. (**B**) Trajectories of three representative cells expressing different levels of EGFP-E2F-1. (**C**) Correlation between RelA-dsRedxp T½ nuclear occupancy (NO) time and EGFP-E2F-1 T½ nuclear degradation time, based on data in (**A**). (**D**) Recapitulation of the observed dynamics with an in silico model for physical interaction between RelA (*NFkB*) and E2F-1 (*E2F)* (**E**) Correlation between NF-κB nuclear occupancy time and nuclear E2F-1 degradation time, based on data in (**D**) (n= 30 cells).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.010](10.7554/eLife.10473.010)10.7554/eLife.10473.011Figure 4---figure supplement 2.E2F-1 modulates NF-κB dynamics in the absence of stimulus in HeLa cells.(**A**) Representative HeLa cells transiently transfected with combinations of RelA and E2F-1 fluorescent fusion proteins. (**B**) Time-lapse confocal microscopy of representative HeLa cells transiently transfected with RelA-dsRedxp and EGFP-E2F-1. (**C**) Trajectories of three representative cells expressing different levels of EGFP-E2F-1. (**D**) Correlation between RelA-dsRedxp T½ nuclear occupancy (NO) time and EGFP-E2F-1 T½ nuclear degradation time, based on data in (**C**) (n=20).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.011](10.7554/eLife.10473.011)

In transient transfection experiments, a predominantly cytoplasmic localization of RelA-DsRedxp was observed when expressed alone, whereas in cells co-expressing EGFP-E2F-1, both proteins were predominantly nuclear ([Figure 4E](#fig4){ref-type="fig"}). In addition we also found that the steady-state cytoplasmic localisation of RelA was restored in cells transiently expressing IκBα-AmCyan in addition to EGFP-E2F-1 and RelA-dsRedxp. These data suggest the hypothesis that IκBα and E2F-1 may compete for the same binding site on RelA, with IκBα perhaps having the higher affinity. Time-series experiments in both SK-N-AS and HeLa cells showed that a decrease in EGFP-E2F-1 expression over time was associated with a re-localization of RelA-DsRedxp from the nucleus to the cytoplasm (for SK-N-AS cells, [Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}; for HeLa cells, [Figure 4---figure supplement 2A--C](#fig4s2){ref-type="fig"}). Quantitative analysis showed a strong correlation between the EGFP-E2F-1 decay half-life and the delay in RelA-DsRedxp translocation back into the cytoplasm (for SK-N-AS cells, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}; for HeLa cells, [Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). Initial mathematical modelling of this interacting system (for details of the model see Appendix Section B) was able to recapitulate the main features of the observed correlation between E2F-1 levels and RelA localization in silico ([Figure 4---figure supplement 1D--E](#fig4s1){ref-type="fig"}).

Physical and functional interaction between RelA and E2F-1 {#s2-4}
----------------------------------------------------------

These data supported a direct interaction between E2F-1 and RelA. Therefore, the physical interactions between E2F-1 and NF-κB proteins in cells were investigated. Co-localization of E2F-1 and RelA had previously been shown through fluorescence imaging experiments (see [Figure 5A](#fig5){ref-type="fig"}). A clear physical interaction between fluorescently labelled E2F-1 and RelA in the nucleus of living cells was evident using Förster Resonance Energy Transfer (FRET), in conjunction with acceptor photobleaching as a qualitative indicator of intermolecular interaction ([Figure 5D](#fig5){ref-type="fig"}), and Fluorescence Cross-Correlation Spectroscopy (FCCS) ([Figure 5C](#fig5){ref-type="fig"}).10.7554/eLife.10473.012Figure 5.Interaction of E2F-1 with RelA.(**A**) Representative cell demonstrating co-localisation of E2F1-EGFP and RelA-dsRedxp upon transient transfection. (**B**) Co-Immunoprecipitation of E2F-1 with RelA pull down in HeLa cells synchronized in late G1 (HeLa cells used for this experiment due to their greater ease of synchronization). (**C**) FCCS assay between transiently transfected EGFP-E2F-1 and RelA-dsRedxp (red line) or empty-dsRedxp (blue line) fluorescent fusion proteins in single live SK-N-AS cells (+/- s.e.m based on 10 measurements from 10+ cells per condition). (**D**) Qualitative FRET assay between transiently transfected ECFP-E2F-1 and RelA-EYFP fluorescent fusion proteins in live SK-N-AS cells. First negative control between IkB-ECFP and EYFP-E2F1, and second negative control between free ECFP and EYFP fluorophores expressed in an SK-N-AS cell (shown are average ECFP and EYFP signals (+/- s.e.m based on 20 cells per condition normalised to pre-bleach intensity. p.b. indicates the time point at which photo-bleaching occurred).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.012](10.7554/eLife.10473.012)

In order to further support the interaction between the endogenous proteins, we used co-immunoprecipitation (Co-IP) of endogenous E2F-1 and RelA in HeLa cells that had been synchronized in late G1, when E2F-1 levels were at their peak ([Figure 5B](#fig5){ref-type="fig"}). These data confirmed a physical interaction between E2F-1 and RelA, in agreement with previous studies ([@bib66]; [@bib40]; [@bib23]). We were not able to observe a positive co-IP in asynchronous cells (see [Appendix 1---figure 4](#fig13){ref-type="fig"}), suggesting that this interaction was only detectable in HeLa cells at G1/S when E2F-1 was at its highest level. Considered together, all of these different measurements support a significant interaction between these proteins. These data suggest the hypothesis that the interaction between RelA and E2F-1 in the nucleus of G1/S cells, which have been subjected to an inflammatory stimulus, may coordinate differential regulation of NF-κB target gene transcription.

In-silico modelling and prediction of NF-κB interaction with E2F-4 {#s2-5}
------------------------------------------------------------------

In order to understand and further investigate the dynamic behaviour of TNF-α-mediated NF-κB activation in the presence of E2F-1 (at the G1-S transition), an ordinary differential equation-based mathematical model of the NF-κB system ([@bib5]) was extended to include the interaction with E2F-1 (see Appendix Section B). In this model, E2F-1 was assumed to compete with IκBα for binding to free NF-κB, but had no effect on the localization of RelA bound to IκBα. Simulations (of nuclear NF-κB levels over time from transfection experiments) using this model, supported the hypothesis that E2F-1 might temporally control the duration of RelA nuclear occupancy through a combination of binding to RelA in the nucleus and inhibition of RelA-dependent IκBα transcription (as suggested by data shown in [Figure 4](#fig4){ref-type="fig"}). E2F-1 degradation could allow NF-κB to re-activate IκBα, which in turn could restore RelA to a cytoplasmic localization.

When the initial mathematical model was used to simulate the effect of E2F-1 on the responsiveness of NF-κB to TNFα, the in silico simulations predicted that TNFα would induce immediate oscillations of free RelA ([Figure 6A](#fig6){ref-type="fig"}). In contrast, time-lapse live cell imaging of SK-N-AS cells stimulated with TNFα, showed that in cells expressing RelA-DsRedxp and EGFP-E2F-1 (which initially had nuclear RelA-DsRedxp), there was a delay before the onset of oscillations ([Figure 6B and D](#fig6){ref-type="fig"}). The length of this refractory period was on average \~4-fold longer than the peak1:peak2 timing in cells expressing RelA-DsRedxp alone ([Figure 6B](#fig6){ref-type="fig"} and \[[@bib5]\]). Altered model structures were investigated in order to resolve this discrepancy between experimental data and model predictions. One of the simplest altered models predicted that an E2F-1 target gene might stabilize IκBα (keeping NF-κB in the cytoplasm during S-phase \[[Figure 6C](#fig6){ref-type="fig"}\]). In support of this prediction, TNFα treatment of SK-N-AS cell populations transiently expressing EGFP-E2F-1 and RelA-DsRedxp led to reduced levels of phospho-S536-RelA and stabilized levels of IκBα ([Figure 6E](#fig6){ref-type="fig"}). Simulations of the response to TNFα from the revised model were consistent with the observed delay in oscillations in single cells expressing ectopic EGFP-E2F-1 ([Figure 6B and D](#fig6){ref-type="fig"}) and also with the inhibition or delay in the response during S-phase, but not during G1 or G2 ([Figure 2C](#fig2){ref-type="fig"}). Candidates for the E2F-1-regulated component(s) predicted by the revised model were therefore sought.10.7554/eLife.10473.013Figure 6.Mathematical modelling predicts an additional key component for NF-κB - cell cycle interactions: E2F-4 identified as a putative candidate.(**A**) Model simulations of RelA-dsRedxp dynamics when co-expressed with EGFP-E2F-1 in cells treated with TNFα. (**B**) Dynamics analysed in representative SK-N-AS cells treated with 10 ng/ml TNFα expressing RelA-dsRedxp and EGFP-E2F-1 (**C**) Model simulation of experimental conditions in B, incorporating interactions between NF-κB complexes and a putative E2F-1-induced target protein, subsequently proposed as E2F-4. (**D**) Analysis of average timing to second peak of NF-κB translocation following TNFα treatment in SK-N-AS cells expressing RelA-dsRedxp alone or with EGFP-E2F-1 (n=20 cells per condition, error bars show s.d.) (**E**) Assessment of the extent of RelA Ser^536^ phosphorylation (p-RelA), E2F-4 and IκBα stability by western blot compared to cyclophilin A (cyclo A) amounts in SK-N-AS cells either untreated or treated with 10 ng/ml TNFα and expressing combinations of either untagged or fluorescent RelA-dsRedxp and EGFP-E2F-1. (**F**) Western blot of E2F-1 and E2F-4 in synchronized HeLa cells, where t=0 is late G1-phase.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.013](10.7554/eLife.10473.013)

Previous studies had shown strong structural homology between E2F-1 and other E2F family members ([@bib69]). E2F-4 is a transcriptional target of E2F-1 ([@bib77]) and can be cytoplasmic during S-phase ([@bib41]). E2F-4 (together with E2F family members) was therefore considered as a prospective candidate. We confirmed that ectopic expression of E2F-1 in cells resulted in increased E2F-4 expression, consistent with E2F-4 being a transcriptional target of E2F-1 in these cells ([Figure 6E](#fig6){ref-type="fig"}). The profile of E2F-4 expression was found to be delayed relative to that of E2F-1 in the cell cycle, peaking in S-phase in synchronized HeLa cells ([Figure 6F](#fig6){ref-type="fig"}).

E2F-4 and RelA physically and functionally interact {#s2-6}
---------------------------------------------------

To further confirm the role of E2F-4 in the suppression of RelA translocation following TNFα treatment during S-phase, the physical and functional interactions between E2F-4 and RelA proteins in cells were investigated. When transiently expressed in either HeLa or SK-N-AS cells, both proteins were located in the cytoplasm ([Figure 7A](#fig7){ref-type="fig"}). Following TNFα treatment, the timing of RelA-DsRedxp translocation to the nucleus in both cell lines was delayed relative to the level of the fluorescent signal from EGFP-E2F-4 ([Figure 7B](#fig7){ref-type="fig"} for dynamic profiles and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"} for analysis). The physical interaction of endogenous E2F-4 and RelA proteins was supported by Co-IP from HeLa cells synchronized in S-phase ([Figure 7C](#fig7){ref-type="fig"}). No pull-down was observed in cells synchronised in late G1 phase (see [Appendix 1---figure 4](#fig13){ref-type="fig"}). This is the cell cycle stage when E2F-1, but not E2F-4 is at its peak expression level. This interaction was confirmed by acceptor photo bleaching FRET and FCCS data obtained from cells transiently expressing ECFP-E2F-4 and RelA-EYFP (for FRET) or RelA-dsRedxp and EGFP-E2F-4 (for FCCS) fluorescent fusion proteins ([Figure 7D and E](#fig7){ref-type="fig"} respectively). These data suggested that members of the E2F family have differing, but functionally linked, roles in the regulation of NF-κB dynamics. The observed dynamics could be represented by a mathematical model that recapitulates data ([Figure 6C](#fig6){ref-type="fig"}) from live cell imaging of the transient expression of the appropriate fluorescent fusion proteins ([Figure 5A](#fig5){ref-type="fig"} and [7A](#fig7){ref-type="fig"}, for details of modelling see Appendix Section B).10.7554/eLife.10473.014Figure 7.E2F-4 directly interacts with NF-κB and perturbs RelA dynamics in response to TNFα stimulation.(**A**) Single cell trajectories from groups of HeLa cells expressing RelA-dsRedxp and different levels of EGFP-E2F-4 showing the dynamics of RelA-dsRedxp after 10 ng/ml TNFα treatment (n=60 cells). (**B**) HeLa cells synchronized in S-phase, co-immunoprecipitated with anti-RelA antibody and probed for E2F-4. Also shown are IgG negative controls and whole cell lysate unsynchronized positive control (ctrl). (**C**) Representative SK-N-AS cells transiently transfected with RelA-dsRedxp and EGFP-E2F-4. (**D**) FRET assay in live SK-N-AS cells expressing ECFP-E2F-4 and RelA-EYFP fluorescent fusion proteins (shown are average ECFP and EYFP signals (+/- s.e.m) based on 20 cells per condition normalised to pre-bleach intensity. p.b. indicates the point of photo-bleaching). (**E**) FCCS assay in cells transiently expressing EGFP-E2F-4 and RelA-dsRedxp (red line) or dsRedxp (blue line) fluorescent proteins in single live SK-N-AS cells (+/- s.e.m based on 10 measurements in each of 10+ cells per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.014](10.7554/eLife.10473.014)10.7554/eLife.10473.015Figure 7---figure supplement 1.Analysis of RelA-dsRedxp dynamics in HeLa and SK-N-AS cells co-expressing EGFP-E2F-4 following TNFα stimulation.The effects of different EGFP-E2F-4 expression levels on the amplitude and timing of the first peak of RelA translocation in HeLa and SK-N-AS cells treated with 10 ng/ml and 30 pg/ml TNFα, respectively. These data indicate how ectopically expressed EGFP-E2F-4 can inhibit the translocation of RelA-dsRedxp in response to TNFα.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.015](10.7554/eLife.10473.015)

Analysis of the effect of the cell cycle on the NF-κB response at more physiological expression levels of E2F-1 {#s2-7}
---------------------------------------------------------------------------------------------------------------

The majority of experiments described above utilised transient expression of the E2F and RelA fusion proteins driven from a CMV promoter in a plasmid vector. Previous data had suggested that RelA fusion proteins expressed in a knock-in mouse are functional and fusion protein expression does not perturb the system ([@bib18]). Our transcription analyses ([Figure 4](#fig4){ref-type="fig"}) suggested that E2F-1 N- and C-terminal fusion proteins also retained functional activity. However, as E2F proteins are normally expressed at specific stages of the cell cycle, ectopic expression from a strong constitutive promoter could give rise to out-of-context expression at inappropriate stages of the cell cycle (i.e. for E2F-1, stages other than late G1 and early S-phase). Therefore, expression of fusion proteins from these vectors might potentially show interactions that are not physiologically relevant. An additional complication in these experiments was that exogenous expression of E2F-1 (but not E2F-4) fluorescent fusion protein from a CMV promoter caused apoptosis when transfected alone. Interestingly this effect was rescued by co-expression with RelA.

To further validate the functional link between the E2F and RelA proteins, we sought to achieve more physiologically relevant levels and timing of the fluorescent fusion protein expression. To this end, stable HeLa cell lines were generated, with integrated Bacterial Artificial Chromosomes expressing E2F-1-Venus and RelA-DsRedxp under the control of their natural human gene promotors and associated regulatory elements (see Appendix Section C). HeLa cells were chosen for this study based on their more consistent cell cycle timing (between cells) compared to SK-N-AS cells (as shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

Stable cell lines were generated with a human E2F-1-Venus BAC construct, and showed the same pattern of synthesis and degradation of a transiently expressed FUCCI reporter for SCF (SKP-2) activity, indicating normal cell cycle progression (see [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). All viable clones had relatively low expression of the E2F-1-Venus BAC, further suggesting that E2F-1 over-expression was detrimental to cell survival. Following the generation of these stable clones, a single clone was selected for the integration of a RelA-DsRedxp BAC into this cell line. This generated a dual stable clone of E2F-1-Venus and Rel-A-DsRedxp (termed C1-1). This clonal cell line showed a slight increase (\~8%) in mean cell cycle length (with similar cell-to-cell variability) comparable with wild type HeLa (see [Appendix 1---figure 7](#fig15){ref-type="fig"}). Similar to wild type cells, TNFα treatment in the C1-1 cell line increased the variability in cell cycle timing compared to that of resting cells.

The slight change in mean cell cycle duration (\~20 hr) in the dual BAC stable clonal cell line C1-1 was taken into account for inference of the dynamics of RelA-DsRedxp translocation at different cell cycle phases. The profile of E2F-1-Venus expression was used for assignment of the cell cycle stage at the time of stimulation cells based upon the time of peak E2F-1-Venus expression ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). This provided an alternative and faster method of virtual synchronisation to that used in [Figure 2](#fig2){ref-type="fig"}, allowing the assignment of G1, S and G2 phases to the data from the simulated BAC stable cells. The level of RelA translocation ([Figure 8B](#fig8){ref-type="fig"}) was then quantified for cells from each cell cycle phase. In agreement with data from the transiently transfected HeLa and SK-N-AS cells ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplements 2](#fig2s2){ref-type="fig"} and [3](#fig2s3){ref-type="fig"}), the cells treated in late G1/S-phase showed higher amplitude RelA nuclear translocations, whereas Cells treated in S-phase showed a statistically significant suppression in S-phase RelA translocation compared to cells in early G1- or G2-phases ([Figure 8](#fig8){ref-type="fig"} and [Figure 8---figure supplement 3](#fig8s3){ref-type="fig"}).10.7554/eLife.10473.016Figure 8.Effect of cell cycle timing on RelA-dsRedXP translocation in dual BAC HeLa cells (C1-1 line) that co-express E2F-1-Venus fusion protein.(**A**) Selected images from time-lapse experiment of dual BAC transfected HeLa stable clone 1-1 showing translocation of RelA-dsRedXP and E2F-1-Venus expression at different cell cycle phases. Cells were treated with 10 ng/ml TNFα. (**B**) Analysis of the dynamics of initial RelA-dsRedxp translocation in cells ordered at specific cell cycle times with respect to the peak of E2F-1 expression (n = 128). Data were analysed using nonparametric Anova analysis with Dunn correction for multiple comparisons. Red lines indicate mean normalised amplitude of NF-κB nuclear translocation for different cell cycle phases, and the population average (dotted red line). Analysis of nuclear RelA occupancy was assessed in virtually synchronised C 1-1 cells, based on time from cell division and relative to peak E2F-1-Venus expression level. RelA-dsRedxp localization was visualized to allow quantification of translocation, following treatment with 10 ng/ml TNFα. The dotted black line shows the spline fitted level of E2F1 at different times and cell cycle stages (see also [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} below). Statistical analysis showed a difference between G1 vs S, and G2 vs S with respect to distribution of amplitude of the RelA translocation response. (**C**) RelA-dsRedxp dynamics following 10 ng/ml TNFα treatment in asynchronous cells (left panel) and cells virtually synchronised into G1, G1/S, S and G2 phases. The data for each cell was normalised to the amplitude (N:C ratio) at t = 0 min.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.016](10.7554/eLife.10473.016)10.7554/eLife.10473.017Figure 8---figure supplement 1.Virtually synchronized HeLa C 1-1 cells.Normalised E2F-1-Venus expression at the time of TNFα stimulation of C1-1 cells (data also shown in Figure 8B). E2F-1-Venus expression was normalised to its peak expression. The time axis represents the time of TNFα stimulation relative to the peak of E2F-1-Venus for each cell, where time 0 is the peak of E2F-1-Venus expression. Positive times indicate stimulation after the peak of E2F-1-Venus expression and negative values indicate stimulation events before the peak of E2F-1-Venus expression. The black line shows a spline interpolation of the level of E2F-1-Venus expression. Cell cycle phases were estimated based on measured the E2F1 profile and average cell cycle timing.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.017](10.7554/eLife.10473.017)10.7554/eLife.10473.018Figure 8---figure supplement 2.Physiological and functional expression of E2F-1-Venus in stable BAC-transduced HeLa cells.(**A**) HeLa cells stably expressing an E2F-1-Venus fluorescent fusion protein from a 5KB endogenous E2F-1 promoter (Green), transiently transfected with a FUCCI reporter for SCF (SKP-2) activity (Orange). Showing the profile of E2F-1 over two consecutive cell cycles (one parent and two daughter cells), with a peak in late G1. E2F-1 levels dropped during S-phase consistent with rapid rise in SCF (SKP-2) activity and a loss of FUCCI fluorescence. (**B**) Representative cell from the E2F-1-Venus and RelA-DsRedxp stably transfected population of Hela cells through one full cell cycle.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.018](10.7554/eLife.10473.018)10.7554/eLife.10473.019Figure 8---figure supplement 3.Analysis of the expression of E2F-1-Venus and RelA-DsRedxp translocation in single C1-1 HeLa cells stimulated with 10ng/ml TNFα at different cell cycle phases.Grey line shows the E2F-1-Venus expression level plotted agains the right y-axis. The red, green blue and orange lines show the timecourse of RelA-dsRedxp localization in exemplar cells in the G1, G1/S, S and G2 phases respectively plotted against the left y-axis. The black vertical line represents the point at which cells were treated with TNFα.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.019](10.7554/eLife.10473.019)10.7554/eLife.10473.020Figure 8---figure supplement 4.Expression and interaction of RelA-dsRedxp and E2F-1-Venus.(**A**) Western blot of RelA and α-tubulin levels in dual BAC stable C1-1 and WT HeLa showing exogenous expression of RelA-dsRedxp. (**B**) Western blot of E2F-1 and cyclophilin A levels in dual BAC stable C1-1 and WT HeLa cells expressing the E2F-1-Venus BAC (**C**) Total fluorescent molecules per cell for E2F1-Venus at peak expression and RelA-dsRedxp in unstimulated cells (data obtained from Fluorescent Correlation Spectroscopy measurements, and calculated using volume estimates from z-stacked WT HeLa in suspension). (**D**) FCCS mean correlation curves (+/- s.e.m) between E2F-1-Venus and RelA-dsRedxp (red line, n=46) for TNFα treated BAC stable cells. A comparison to transient empty-dsRedxp is shown (blue line, n=15) (**E**) Kd determination results using a scatter plot and linear regression (Theil-Sen estimator). The slope of the regression gives the Kd value.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.020](10.7554/eLife.10473.020)

Expression of the RelA-DsRedxp and E2F-1-Venus fusion proteins in the stable cell line was quantified through molecular counting of fluorophores via FCS ([Figure 8---figure supplement 4](#fig8s4){ref-type="fig"}). This gave an estimate of 310,000 ± 120,000 molcules of RelA-DsRedxp per cell. This figure was comparable to previous molecular estimates using FCS that had been obtained in stable cell lines generated using lentivirus ([@bib6]), and previous estimates of RelA concentration using analytical chemistry ([@bib45]; [@bib81]). RelA showed an approximate ratio of 3:1 ectopic to endogenous expression based on quantitative analysis of western blot data (see [Figure 8---figure supplement 4A](#fig8s4){ref-type="fig"}). By contrast, FCS analysis suggested that E2F-1-Venus expression was lower (24,000 ± 9100 molecules of E2F-1-Venus per cell). Western blot analysis ([Figure 8---figure supplement 4B](#fig8s4){ref-type="fig"}) suggested that there was an approximate ratio of 10:1 endogenous to ectopic levels). This might suggest selective pressure during cloning, as over-expression of E2F-1 has been reported to compromise cell viability ([@bib17]). The apparent selective pressure against higher E2F-1 fusion protein expression was also in agreement with our own data that suggested that transient exogenous expression of E2F-1 fusion protein (but not E2F-4) alone caused apoptosis, but that this was rescued by co-expression of RelA. In the same manner observed with low EGFP-E2F1 expression from transient co-expression, the more physiological levels of E2F-1-Venus expression in the stably transfected cells suggested that RelA-DsRedxp remained predominantly cytoplasmic in unstimulated cells.

The interaction between E2F-1-Venus and RelA-DsRedxp following TNFα stimulation was measured by Fluorescence Cross-Correlation Spectroscopy (FCCS). A strong cross-correlation was confirmed in the nucleus ([Figure 8---figure supplement 4D](#fig8s4){ref-type="fig"}) indicating that the interaction uncovered by transient transfection with plasmids was not an artefact of over-expression, but was contextually relevant in relation to the cell cycle and RelA activation. Analysis of the dissociation constant (by FCCS) for the RelA-DsRedxp and E2F-1-Venus binding in the nucleus of TNFα--stimulated cells suggested a dissociation constant (K~d~) of 12 nM ([Figure 8E](#fig8){ref-type="fig"}).

The stable and physiological co-expression of E2F-Venus and RelA-DsRedxp facilitated fluorescently labelled proteins to be observed over the course of a full cell cycle. Cells were virtually synchronized as previously described following stimulation with 10 ng/ml TNFα, and translocation of RelA-DsRedxp was plotted against the nuclear expression of E2F-1-Venus ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}).

We also investigated the consequences of knocking down both E2F-1 and E2F-4 using siRNA. Imaging experiments showed E2F-1 knockdown did not prevent cell cycle progression, and did not affect the heterogeneity of population response upon TNFα stimulation (data not shown), perhaps indicating compensation by other E2F family members. In addition, our mathematical model predicted that knocking down E2F-1 might not substantially affect the repression of the NF-κB response in S-phase, which was instead predicted to be due to the effect of E2F-4 expression. However, knock-down of E2F-4 was found to be lethal to cells ([@bib17]) preventing time lapse analysis. A key additional consideration is the overlapping roles of other E2F family members, which makes knock-down of individual E2F proteins unpredictable, due to potentially co-operative and/or redundant functions.

Discussion {#s3}
==========

Biological timing plays a key role in the encoding and decoding of biological information. Of particular interest is the role of biological oscillators, which can have very different cycle periods. A key question is how they may interact to robustly control essential biological processes. Here, we propose a reciprocal relationship between two oscillators, NF-κB signalling and the cell cycle.

TNFα stimulation in S-phase showed a suppressed and delayed translocation of RelA, with no observable perturbation to cell cycle timing. In contrast, stimulation in late G1 showed strong translocation of RelA ([Figure 2](#fig2){ref-type="fig"}) and led to significant lengthening of the cell cycle ([Figure 3](#fig3){ref-type="fig"}). These data suggest that cells use the G1/S checkpoint to prioritize between inflammatory signalling and the onset of DNA replication prior to cell division (see schematic diagram in [Figure 9](#fig9){ref-type="fig"}). The presence of a mechanism for prioritization between the important processes of cell proliferation and inflammation suggests that an inflammatory response during DNA replication might be detrimental to the cell.10.7554/eLife.10473.021Figure 9.Schematic representation of NF-κB -- E2F interactions.(**A**) Predicted mechanisms for NF-κB interaction with E2F proteins over the G1/S transition (**B**) Model simulations of single cell behaviour.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.021](10.7554/eLife.10473.021)

The data showing that TNFα stimulation alters cell cycle timing in a cell cycle phase-dependent manner is intriguing ([Figure 3](#fig3){ref-type="fig"}). However, our data do not identify a specific mechanism by which TNFα may regulate cell cycle length. The observation that the effect of TNFα stimulation on cell cycle lengthening appears to be specific to G1/S- rather than S-phase suggests that this may occur by delaying transition through the G1/S checkpoint. One hypothesis is that this might occur through NF-κB modulation of E2F family transcriptional activity. At the same time, the system is more complex as NF-κB is known to regulate the expression of other key cell cycle regulating proteins. Important examples include Cyclin D ([@bib25]; [@bib29], [@bib61]), and p21^waf1/cip1^ ([@bib8]). Therefore, there is undoubtedly a more complex set of interactions between NF-κB and the control of cell proliferation and cancer ([@bib54]).

As well as a number of studies that suggest a physical interaction between E2F and NF-κB proteins ([@bib36]; [@bib14]; [@bib66], [@bib62]; [@bib50]), there have been a few previous studies that have suggested that this interaction might have functional importance. Araki *et al*. described an NF-κB-dependent mechanism for growth arrest mediated by a dual mechanism. They suggested that E2F-1-dependent transcription was inhibited by IKK activation and that E2F-4 was phosphorylated directly by IKK resulting in increased activity of the E2F-4/p130 repressor complex ([@bib3]). Their study did not assume direct interactions between the E2F and Rel proteins and did not take into account protein dynamics. Nevertheless, their conclusions are very complementary to the present study.

Another study by Tanaka et al. focused on the combined role of E2F-1 and c-MYC in the inhibition of NF-κB activity ([@bib66]). This study demonstrated interactions between E2F-1 and both RelA and p50. Rather than focusing on cell division, their study showed that inhibition of RelA activity by E2F-1 resulted in increased apoptosis. Since both the NF-κB and E2F families of transcription factors have important roles in the control of apoptosis ([@bib56]; [@bib35]; [@bib17]), it is therefore interesting to speculate that the levels of different E2F proteins at different cell cycle stages may regulate cell fate decision making in collaboration with signalling systems such as NF-κB.

One important conclusion of the current study is the physical interaction of RelA with E2F-1 and E2F-4 proteins. It is however not necessary to assume strong binding and sequestration into different cellular compartments. Instead, control of cross-talk could be a consequence of mutual control of gene expression. We provide some data that suggests that E2F-1 and IκBα may compete for binding to RelA (see [Figure 4E](#fig4){ref-type="fig"}). We suggest that control may be achieved through repression of the IκBα feedback loop (and perhaps other negative feedbacks, such as A20). However, it might be that other genes are differentially activated through the combined action of these transcription factors. In support of this, Garber *et al.* performed a study in dendritic cells where they studied a panel of transcription factors by ChIP-Seq following LPS stimulation. Their data suggested that E2F-1 and RelA are common transcription factor pairs that were bound together at a large set of functionally important gene promoters (see data in [Figure 3B](#fig3){ref-type="fig"} of [@bib23]). It therefore seems likely that these proteins mutually regulate patterns of transcriptional activity, controlling the expression of downstream feedback genes, cell proliferation and apoptosis.

We describe a mechanism for E2F-1 that suggests competition with IκBα for NF-κB binding. This was effectively described by the model (see also [Figure 9](#fig9){ref-type="fig"}), and was used to predict the role for an E2F-1 target gene, upregulated in S-phase. Our data support E2F-4 as a candidate for this E2F-1 target gene. It should be noted however, that the E2F family of proteins may all play a role in this complex system. A surprising characteristic of E2F-4 is its predominantly cytoplasmic localisation in some cell types. As a result, we were unable to perform a competition localisation experiment (as for E2F-1, [Figure 4E](#fig4){ref-type="fig"}). We cannot therefore comment on whether E2F-4 also competes with IκBα for RelA binding. Therefore, the model (both mathematical model and schematic model in [Figure 9](#fig9){ref-type="fig"}) encode E2F-4 binding as a ternary complex to RelA and IκBα together. We stress that this is only one possible mechanism, but we have used this formulation since it is the simplest model that is consistent with all of our data. As described by Araki *et al.* (see above) there may be other components involved such as IKK-mediated E2F-4 phosphorylation ([@bib2]).

Functional and context-dependent coupling between dynamic cellular processes (such as the cell cycle, the circadian clock \[[@bib78]; [@bib11]; [@bib20]\], or p53 \[[@bib68]\]) is emerging as a common theme in intracellular signalling ([@bib1]; [@bib74]; [@bib64]). The present study has characterized a dynamic and functional interaction between NF-κB and the cell cycle systems, which each oscillate with different periods. Coupling between cellular processes (e.g. at the G1/S commitment point) can have contrasting effects on cell fate. Such temporal communication between processes represents a way for cells to gate their biological signals and coordinate and prioritize cell fate decisions in response to changes in their environment. In a wider context, understanding how (and when) these dynamic interactions occur could yield important therapeutic targets for fields such as cancer chronotherapy ([@bib16]; [@bib44]).

Materials and methods {#s4}
=====================

Materials {#s4-1}
---------

Human recombinant TNFα was supplied by Calbiochem (UK). Tissue culture medium was supplied by Invitrogen (UK) and Fetal Bovine Serum (FBS) was from Harlan Seralab (UK). All other chemicals were supplied by Sigma (UK) unless stated otherwise.

Plasmids {#s4-2}
--------

All plasmids were propagated using *E. coli* DH5α and purified using Qiagen Maxiprep kits (Qiagen, UK). NF-κB-Luc (Stratagene, UK) contains five repeats of an NF-κB-sensitive enhancer element upstream of the TATA box, controlling expression of luciferase. Luciferase reporter CyclinE-Luc was obtained from Peggy Farnham (University of Wisconsin-Madison, USA). EGFP-E2F-1 and EGFP-E2F-4 contain the Enhanced Green Fluorescent Protein (EGFP) gene (Invitrogen, UK) fused to the N-terminal ends of the human E2F-1 and E2F-4 gene fragments (kind gifts from Emmanuelle Trinh, BRIC, Denmark). Similarly, ECFP-E2F-1 and ECFP-E2F-4 contain the Enhanced Cyan Fluorescent Protein (ECFP) gene (Invitrogen, UK) RelA-DsRedxp contain the optimised DsRed Express protein (DsRedxp) gene (Clontech, CA) fused to the c-terminal end of human RelA gene (described previously in [@bib48]. RelA-EYFP contain Enhanced Yellow Fluorescent protein (EYFP) gene (Invitogen, UK) fused to the C-terminal end of human RelA gene.

Cell culture {#s4-3}
------------

SK-N-AS neuroblastoma (cat.no. 94092302) and HeLa cervical carcinoma (Cat. No. 93021013) cell lines were obtained from European Collection of Authenticated Cell Cultures (ECACC). Cells were cultured and frozen down to form a low passage working stock. Subsequent working stocks were used for no more than 10 passages. Working stocks were screened to ensure the absence of mycoplasma every 3 months using LookOut Mycoplasma PCR Detection Kit (Cat. No. D9307 Sigma, UK). For confocal fluorescence microscopy and immuno-cytochemistry, SK-N-AS and HeLa cells were plated on 35 mm glass-bottom dishes (Iwaki, Japan and Greiner, Germany) at 1x10^5^ cells per dish in 3 ml medium. HeLa cells were plated at 5x10^4^ cells per dish in 3 ml medium. 24 hr post-plating, the cells were transfected with the appropriate plasmid(s) using Fugene 6 (Boehringer Mannheim/Roche, Germany). The optimized ratio of DNA:Fugene 6 used for transfection of HeLa or SK-N-AS cells was 2 µg DNA with 4 µl Fugene 6 and 0.8 µg DNA with 1.2 µl Fugene 6 respectively.

For Co-IP assays, SK-N-AS cells were plated on 100 mm tissue culture dishes (Corning, USA) at 4.5x10^6^ cells per dish in 10 ml medium. For western blotting, semi-quantitative and quantitative PCR, HeLa and SK-N-AS cells were plated on 60 mm tissue culture dishes (Corning, USA) at 5x10^5^ and 1x10^6^ cells respectively per dish in 5 ml medium.

G1/S Cell cycle synchronisation via double Thymidine block {#s4-4}
----------------------------------------------------------

24 hr post-plating, 2 mM Thymidine was added to the culture medium. Following a 19 hr incubation, cells were washed and fresh medium added. Following a 9 hr incubation, 2 mM Thymidine was again added to the culture medium and the cells incubated for a further 16 hr. Cells were then washed and fresh media added. Following release from Thymidine block, the G1/S-synchronized cells were either imaged or incubated (at 37°C, 5% CO~2~) for the indicated duration prior to cell lysis or fixation.

Treatment of cells with TNFα {#s4-5}
----------------------------

For confocal fluorescence microscopy, the cells were treated in-situ between imaging acquisitions after an indicated pre-treatment incubation period (usually 24 hr post-transfection). For western blotting and q-PCR experiments, the cells were treated with TNFα 24 hr post-plating. The cells were imaged either immediately after treatment, or incubated (at 37°C, 5% CO~2~) for the indicated duration prior to cell lysis or fixation.

Fluorescence microscopy {#s4-6}
-----------------------

Confocal microscopy was carried out as described ([@bib47]) using either 20x Fluar 0.8 NA or 63x Planapochromat 1.4 NA objectives. CellTracker ([@bib63]; [@bib19]) was used for data extraction. For RelA fusion proteins, mean fluorescence intensities were calculated for each time point for both nucleus and cytoplasm then nuclear:cytoplasmic (N:C) fluorescence intensity ratios were determined. For time lapse microscopy, a modified version of the Autofocus macro (an improved version of the Autotimeseries macro \[[@bib57]\]) was used.

Analysis of cell cycle progression {#s4-7}
----------------------------------

The cell cycle duration and G1/S timing of SK-N-AS and HeLa cells was analysed using live-cell imaging of successive cell divisions to determine typical cell cycle duration. In addition, the cell cycle dynamics were quantified expressing Fluorescence Ubiquitin-based Cell Cycle Indicators (FUCCI, \[[@bib59]\]) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The crossing point in fluorescent levels from FUCCI markers of APC and SCF E3 ubiqutin ligase was used as an indication of G1/S transition in the cells ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Mitosis to mitosis timings were determined in non-transfected cells, as well as in cells transfected with RelA-dsRedXP and the dual BAC cell line ([Appendix 1---figure 7](#fig15){ref-type="fig"}) For the BAC cell line that expressed E2F-1-Venus it was only possible to use the single SCF FUCCI G1 vector (due to fluorescent protein spectral overlap).

Virtual synchronization {#s4-8}
-----------------------

Cells were imaged for \~30 hr prior to TNFα treatment in order to capture each cell passing through mitosis. The timing of TNFα treatment relative to mitosis for each cell was then calculated. Events following TNFα treatment (i.e. the dynamics of RelA-DsRedxp translocation, or cell cycle duration) could then be correlated to inferred cell cycle phase at the point of treatment. Dual BAC cell lines were imaged for an entire cell cycle. Cells were aligned based upon normalised peak amplitude of E2F-1-Venus, and virtually synchronised based upon alignment of peak E2F-1 expression and the relative timing of TNFα stimulation. Cell cycle boundaries were inferred through characterization of cell cycle progression through transfection of FUCCI G1 phase marker construct ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

Flow cytometric DNA analysis {#s4-9}
----------------------------

HeLa cells were cultured in 100 mm dishes. Following trypsinization, and resuspension in 1 ml of medium the cells were stained by addition of 250 μl of 50 μg/ml propidium iodide, 0.15% TritonX-100, and 150 μg/ml RNase A before analysis in an Altra flow cytometer (Beckman Coulter).

Förster resonance energy transfer (FRET) microscopy {#s4-10}
---------------------------------------------------

FRET was carried out using a Zeiss LSM510 with \'META\' spectral detector mounted on an Axiovert 100S microscope with a 63x Planapochromat, 1.4 NA oil-immersion objective (Zeiss). ECFP and EYFP ([@bib32]) were excited with 458 nm laser light, emitted fluorescence was collected in 8 images each separated by 10 nm between 467 nm and 638 nm in lambda scanning mode. Separation of ECFP and EYFP fluorescence spectra was carried out using the linear unmixing algorithms of the Zeiss LSM510 software (Zeiss), using reference spectra taken from cells expressing the ECFP or EYFP fusion proteins alone or untransfected cells. The fluorescence spectrum was separated into ECFP, EYFP and background signals. FRET was assayed by acceptor (EYFP) photo-bleaching. Bleaching was accomplished using 50 iterations of 514 nm laser light with no attenuation from the acousto-optical tuneable filter (AOTF).

Fluorescence correlation spectroscopy (FCS) and fluorescence cross-correlation spectroscopy (FCCS) {#s4-11}
--------------------------------------------------------------------------------------------------

FCS and FCCS was carried using either a Zeiss LSM780 or Zeiss 710 with Confocor 3 mounted on an AxioObserver Z1 microscope with a 63x C-apochromat, 1.2 NA water-immersion objective. Zen 2010B software was used for data collection and analysis. EGFP fluorescence was excited with 488nm laser light and emission collected between 500 and 530 nm. DsRed-express was excited with 561nm laser light and emission collected between 580 and 630 nm. The protocols as outlined in Kim *et al*. ([@bib34]) were followed, with 10 x 10 s runs used for each measurement. FCS was used to quantify the total number of fluorescent molecules per cell as previously described ([@bib6]). The confocal volume had previously been estimated at 0.59 ± 11 fL (mean ± SD) using Rhodamine 6G of known diffusion rate, and WT HeLa cells in suspension were imaged by confocal microscopy to give volume estimates of 1420 ± 490 fL and 6110 ± 3580 fL for nucleus and cytoplasm respectively. (For FCCS controls see Appendix Section E).

Co-immunoprecipitation {#s4-12}
----------------------

HeLa cells synchronized at G1/S or S-phase were washed with room temperature PBS and lysed with modified RIPA buffer (50 mMTris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40) including a 1:100 dilution of Protease Inhibitor cocktail (Sigma, UK), PMSF and phosphatase inhibitor (Phos Stop, Roche). Immunoprecipitation was carried out using Immunoprecipitation kit-Dynabeads Protein G (Invitrogen) with anti-RelA antibody (\#3034, Cell Signaling, MA, USA). The samples were analyzed by western blotting using anti-E2F-1(Cell Signaling, \#3742) or anti E2F-4 (Santa Cruz, C-20 sc-866) antibodies.

q-PCR {#s4-13}
-----

The RNeasy Mini Kit (Invitrogen, UK) was used to extract mRNA from the cells following manufacturer's instructions, using the primers: IκBα left TGGTGTCCTTGGGTGCTGAT right GGCAGTCCGGCCATTACA, IκBε left GGACCCTGAAACACCGTTGT right CCCCAGTGGCTCAGTTCAGA, E2F-1 left TGCAGAGCAGATGGTTATGG right TATGGTGGCAGAGTCAGTGG, cyclophilin A left GCTTTGGGTCCAGGAATG right GTTGTCCACAGTCAGCAATGGT.

Luciferase reporter assay {#s4-14}
-------------------------

Luciferase reporter assay were carried out as described in [@bib73], using a LUMIstar plate reading luminometer (BMG, Germany).

Immuno-cytochemistry (ICC) {#s4-15}
--------------------------

HeLa cells were prepared using combinations of the above techniques, typically involving synchronization and/or TNFα stimulation of cells seeded at appropriate density into 35 mm glass-bottomed dishes. Dishes were subsequently washed three times with PBS and fixed with 1 ml 4% paraformaldehyde for 15 min. Dishes were then washed three times with PBS, and 'blocked' to prevent non-specific antibody binding with the addition of 1--2 ml of 1% BSA, 0.1% Triton X-100 (in PBS) from 20 min up to overnight. The primary antibody (or antibodies for dual-staining), dissolved in Ab Buffer (1% BSA, 0.1% Triton X-100 in PBS), were added to the dishes for 60/90 min at a 1:2000 dilution. Dishes were then washed (3x1 ml) with Ab buffer for 10 min. Secondary Antibody(s) were subsequently added to the dishes (Cy3-anti-mouse, 1:200 dilution (Sigma), FITC Rabbit, 1:200 \[AbCam\]) for 30/45 min respectively, prior to 3 sequential washes of PBS blocking buffer (described above). Following the addition of fluorescent secondary antibodies, dishes were covered in aluminium foil and left in 2 ml PBS prior to imaging.

Western blotting {#s4-16}
----------------

Whole cell lysates were prepared at the indicated times after stimulation. Membranes were probed using the following antibodies: anti-IκBα (\#9242, Cell Signaling, MA), anti-RelA (\#3034, Cell Signaling, MA), anti-phospho-RelA (Ser 536) (\#3031, Cell Signaling, MA), anti-IκBα (\#9242, Cell Signaling, MA), anti-E2F-1 (\#KH-95, Millipore Biotechnology, USA), anti-E2F-4 (sc-866, Santa Cruz), α-Tubulin Antibody (\#2144 Cell Signaling, MA), and anti-cyclophilin A (\#07--313, Millipore Biotechnology, USA).
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Major datasets {#s7}
--------------

The following dataset was generated:

Ankers JM, Awais R, Jones NA, Boyd J, Ryan S, Adamson AD, Harper CV, Bridge L, David G Spiller, Dean A Jackson, Pawel Paszek, Violaine Sée, Michael RH White,2015,Data from: Dynamic NF-κB and E2F interactions control the priority and timing of inflammatory signalling and cell proliferation.,<https://dx.doi.10.5061/dryad.th18q>,Available at Dryad Digital Repository under a CC0 Public Domain Dedication

Section A: Thymidine synchronisation and analysis {#s31}
=================================================

![Oscillations in the NF-κB system.\
(**A**) Dynamics of RelA-dsRedxp in transiently transfected SK-N-AS cells following 10 ng/μl TNFα stimulation, plotted over 450 and 150 min respectively. (**B**) Dynamics of RelA-dsRedxp in transiently transfected HeLa cells following 10 ng/μl TNFα stimulation, plotted over 450 and 150 min respectively.\
**DOI:** [http://dx.doi.org/10.7554/eLife.10473.022](10.7554/eLife.10473.022)](elife-10473-app1-fig1){#fig10}

![Use of double-Thymidine block to synchronize HeLa cells at G1/S.\
Flow cytometric analysis of the distribution of DNA content of non-synchronized HeLa cells and cells harvested at relevant times post-release from Thymidine block.\
**DOI:** [http://dx.doi.org/10.7554/eLife.10473.023](10.7554/eLife.10473.023)](elife-10473-app1-fig2){#fig11}

![Effect of Double-Thymidine block on tagged and endogenous RelA levels HeLa cells.\
Endogenous RelA and tagged RelA-DsRedxp expression levels in unsynchronised and synchronised WT-HeLa and double BAC stable cells. Synchronized fractions at 0, 2 and 4 hr post release of thymidine block. α-Tubulin used as loading control.\
**DOI:** [http://dx.doi.org/10.7554/eLife.10473.024](10.7554/eLife.10473.024)](elife-10473-app1-fig3){#fig12}

![Negative Co-IP. \
(**A**) Co-Immunoprecipitation of E2F-1 with RelA (pulled down with a RelA antibody) in asynchronous HeLa cells showing no detectable band of E2F-1. (**B**) Co-Immunoprecipitation of E2F-4 with RelA (pulled down with a RelA antibody) in HeLa cells synchronized in late G1-phase cells showing no detectable band of E2F-4.\
**DOI:** [http://dx.doi.org/10.7554/eLife.10473.025](10.7554/eLife.10473.025)](elife-10473-app1-fig4){#fig13}

Section B: The NF-κB:E2F mathematical models {#s32}
============================================

All modelling work was implemented using MATLAB2010 (MathWorks, USA), and simulated using MATLAB ordinary differential equation solver ODE15s. Analysis of simulated time course data was performed in both Microsoft Excel and MATLAB.

Model equations and parameters are shown in SI [Appendix 1---table 2](#A1-tbl2){ref-type="table"} and [3](#A1-tbl3){ref-type="table"} respectively. The deterministic model of TNFα-induced NF-κB signalling ([@bib5]), consisting of a system of ordinary differential equations for species concentrations with respect to time, was extended in two steps. Firstly, the physical interaction between E2F-1 and RelA was included. It was assumed that E2F-1 competes with IκBα for binding of free NF-κB with similar affinity. In addition, free IκBα actively disrupted the NF-κB:E2F-1 complex, while IκBα:NF-κB complex was unaffected by free E2F-1. Secondly, the physical interaction between cytoplasmic NF-κB complexes and E2F-4 was included. E2F-4 was modelled as an E2F-1 responsive gene which, upon translation, forms complexes with NF-κB and NF-κB:IκBα, which were not targeted by IKK. This reduced the system sensitivity to TNFα treatment for a prolonged period.

A typical simulation experiment involved three sequential stages: equilibration, transfection and TNFα treatment (shown below):

1.  The model was initialized by setting neutral IKK and cytoplasmic IκBα:NF-κB to 0.1 μM and other variables to 0. The system was then equilibrated for 1000 min to reach the untreated steady state.

2.  Initial conditions from the end of the equilibrium stage were amended to mimic cell transfection. For example, in the case of E2F-1 and RelA co-transfection 0.1 μM cytoplasmic protein was added to the respective initial conditions.

3.  The equilibrated and transfected model was simulated for 800 min (with TR set to either 1 or 0 depending on whether treatment was simulated or not).

Simulations of the full model are shown below. Simulation protocols used throughout the manuscripts are summarized below.10.7554/eLife.10473.026Appendix 1---figure 5.A typical simulation protocol of the NF-κB:E2F-1 mathematical model.Simulation protocol of a live cell imaging experiment involving transfection and TNFα stimulation.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.026](10.7554/eLife.10473.026)10.7554/eLife.10473.027Appendix 1---table 1.A Initial conditions for the NF-κB:E2F mathematical model. Concentrations of NF-κB and E2F-1 added to mimic cell transfection are also included.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.027](10.7554/eLife.10473.027)SpeciesBiological nameInitial Conditions\
Equilibration stage(μM)Initial Conditions\
TNFα stimulation\
(μM)*NFkB*Cytoplasmic RelA00.004 (+0.1)*nNFkB*Nuclear RelA00.015*E2F1*Cytoplasmic E2F100 (+0.1)*nE2F1*Nuclear E2F100*tIkBa*IκBα mRNA01e-005*IkBa*Cytoplasmic IκBα00.017*nIkBa*Nuclear IκBα00.004*IKKn*Neutral IKK0.10.1*IKK*Active IKK00*IKKi*Inactive IKKi00*tA20*A20 mRNA01e-005*A20*A2000.001*pIkBa*phospho-IκBα00*pIkBaNFkB*phospho-IκBα RelA complex00*NFkBE2F1*cyto. RelA E2F-1 complex00*nNFkBE2F1*nuclear RelA E2F-1 complex00*IkBaNFkB*cyto IκBα RelA complex0.10.091*nIkBaNFkB*nuclear IκBα RelA complex00.001*tE2F4*E2F-1 target E2F-4 mRNA00*E2F4*E2F-1 target E2F-400*E2F4NFkB*E2F-4 RelA complex00*E2F4IkBaNFkB*E2F-4 IκBα RelA complex0010.7554/eLife.10473.028Appendix 1---table 2.NF-κB:E2F-1 model equations Symbol 'n' denotes nuclear variables,'t' denotes mRNA transcripts, 'p' denotes phosphorylated form of IκBα. Symbols denoting cytoplasmic localisation were omitted.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.028](10.7554/eLife.10473.028)$\begin{array}{l}
{\frac{d}{dt}NF\kappa B(t) = - ka1a\, \times \, I\kappa B\alpha(t)\, \times \, NF\kappa B(t) + kd1a\, \times \,(I\kappa B\alpha:NF\kappa B)(t) - ki1\, \times \, NF\kappa B(t)} \\
{+ ke1\, \times \, nNF\kappa B(t) + kt2a\, \times \,(pI\kappa B\alpha:NF\kappa B)(t) + c5a\, \times \,(I\kappa B\alpha)(t)} \\
{+ kd2e\, \times \,(NF\kappa B:E2F1)(t) - ka2e \times E2F1(t) \times NF\kappa B(t) + c8ne \times (NF\kappa B:E2F1)(t)} \\
{- ka3e \times NF\kappa B(t) \times E2F4(t) + kd3e \times (E2F4:NF\kappa B)(t) + c4x \times (E2F4:NF\kappa B)(t)} \\
\end{array}\text{\textbackslash eqno}{(1)}$\
$\begin{array}{l}
{\frac{d}{dt}nNF\kappa B(t) = + ka1a \times nI\kappa B\alpha(t) \times nNF\kappa B(t) + kd1a \times (nI\kappa B\alpha:nNF\kappa B)(t)} \\
{+ ki1 \times kv \times NF\kappa B(t) - ke1 \times kv \times nNF\kappa B(t)} \\
{+ kd2e \times (nNF\kappa B:nE2F1)(t) - ka2e \times nE2F1(t) \times nNF\kappa B(t) + c9ne \times (nNF\kappa B:nE2F1)(t)} \\
\end{array}\text{\textbackslash eqno}{(2)}$\
$\begin{array}{l}
{\frac{d}{dt}E2F1(t) = - kie \times E2F1(t) - kee \times kv \times nE2F1(t) - c6e \times E2F1(t)} \\
{+ kd2e \times (NF\ \kappa B:E2F1)(t) - ka2e \times nE2F1(t) \times NF\ \kappa B(t)} \\
{+ kdis \times (NF\ \kappa B\ :E2F1)(t) \times I\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(3)}$\
$\begin{array}{l}
{\frac{d}{dt}nE2F1(t) = + kie \times kv \times E2F1(t) - kee \times kv \times nE2F1(t) - c7e \times nE2F1(t)} \\
{+ kd2e \times (nNF\ \kappa B:nE2F1)(t) - ka2e \times nE2F1(t) \times nNF\ \kappa B(t)} \\
{+ kdis \times (nNF\ \kappa B\ :nE2F1)(t) \times nI\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(4)}$\
$\begin{array}{l}
{\frac{d}{dt}tI\kappa B\alpha(t) = + c1a \times {\frac{nNF\kappa B^{h}(t)}{nNF\kappa B^{h}(t) + k^{h}} - c3a \times tI\kappa B\alpha(t)}} \\
\end{array}\text{\textbackslash eqno}{(5)}$\
$\begin{array}{l}
{\frac{d}{dt}I\kappa B\alpha(t) = kd1a \times (I\kappa B\alpha:NF\kappa B)(t) - ka1a \times I\kappa B\alpha(t) \times NF\kappa B(t) + c2a \times tI\kappa B\alpha(t)} \\
{- c4a \times I\kappa B\alpha(t) - ki3a \times I\kappa B\alpha(t) + ke3a \times nI\kappa B\alpha(t) - kc1a \times IKK(t) \times I\kappa B\alpha(t)} \\
{- kdis \times (NF\kappa B:E2F1)(t) \times I\kappa B\alpha(t) - ka3e \times (NF\kappa B:E2F4)(t) \times I\kappa B\alpha(t)} \\
{+ kd3e \times (E2F4:I\kappa B\alpha:NF\kappa B)(t)} \\
\end{array}\text{\textbackslash eqno}{(6)}$\
$\begin{array}{l}
{\frac{d}{dt}nI\kappa B\alpha(t) = kd1a \times (nI\kappa B\alpha:nNF\kappa B)(t) - ka1a \times NI\kappa B\alpha(t) \times nNF\kappa B(t)} \\
{- c4a \times nI\kappa B\alpha(t) + ki3a \times kv \times I\kappa B\alpha(t) - ke3a \times kv \times nI\kappa B\alpha(t)} \\
{- kdis \times (nNF\kappa B:nE2F1)(t) \times nI\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(7)}$\
$\begin{array}{l}
{\frac{d}{dt}IKKn(t) = kp \times (\frac{kbA20}{kbA20 + TRA20 \times A20(t)}) \times IKKi(t) - TR \times ka \times IKKn(t)} \\
\end{array}\text{\textbackslash eqno}{(8)}$\
$\begin{array}{l}
{\frac{d}{dt}IKK(t) = TR \times ka \times IKKn(t) - ki \times IKK(t)} \\
\end{array}\text{\textbackslash eqno}{(9)}$\
$\begin{array}{l}
{\frac{d}{dt}IKKi(t) = ki \times IKK(t) - kp \times \frac{kbA20}{kbA20 + TRA20 \times A20(t)} \times IKKi(t)} \\
\end{array}\text{\textbackslash eqno}{(10)}$\
$\begin{array}{l}
{\frac{d}{dt}tA20(t) = + c1 \times \frac{nNF\kappa B^{h}(t)}{nNF\kappa B^{h}(t) + k^{h}} - c3 \times tA20(t)} \\
\end{array}\text{\textbackslash eqno}{(11)}$\
$\begin{array}{l}
{\frac{d}{dt}A20(t) = c2 \times tA20(t) - c4 \times A20(t)} \\
\end{array}\text{\textbackslash eqno}{(12)}$\
$\begin{array}{l}
{\frac{d}{dt}pI\kappa B\alpha(t) = kc1a \times IKK(t) \times I\kappa B\alpha(t) - kt1\alpha \times pI\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(13)}$$\begin{array}{l}
{\frac{d}{dt}(pI\kappa B\alpha:NF\kappa B)(t) = \kappa c2\alpha \times IKK(t) \times (I\kappa B\alpha:NF\kappa B)(t) - \kappa t2\alpha \times (pI\kappa B\alpha:NF\kappa B)(t)} \\
\end{array}\text{\textbackslash eqno}{(14)}$\
$\begin{array}{l}
{\frac{d}{dt}(NF\kappa B:E2F1)(t) = ka2e \times E2F1(t) \times NF\kappa B(t) - kd2e \times (NF\kappa B:E2F1)(t)} \\
{- kine \times (NF\kappa B:E2F1)(t) + kene \times (nNF\kappa B:nE2F1)(t) - c8ne \times (NF\kappa B:E2F1)(t)} \\
{- kdis \times (NF\kappa B:E2F1)(t) \times I\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(15)}$$\begin{array}{l}
{\frac{d}{dt}(nNF\kappa B:nE2F1)(t) = ka2e \times nE2F1(t) - nNF\kappa B(t) - kd2e \times (nNF\kappa B:nE2F1)(t)} \\
{+ kine \times kv \times (NF\kappa B:E2F1)(t) - kene \times kv \times (nNF\kappa B:nE2F1)(t)} \\
{- c9ne \times (nNF\kappa B:nE2F1)(t) - kdis \times (nNF\kappa B:nE2F1)(t) \times nI\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(16)}$\
$\begin{array}{l}
{\frac{d}{dt}(I\kappa B\alpha:NF\kappa B)(t) = ka1a \times I\kappa B\alpha(t) \times NF\kappa B(t) - kd1a \times (I\kappa B\alpha:NF\kappa B)(t)} \\
{- c5a \times (I\kappa B\alpha:NF\kappa B)(t) + ke2a \times (nI\kappa B\alpha:nNF\kappa B)(t)} \\
{- kc2a \times IKK(t) \times (I\kappa B\alpha:NF\kappa B)(t) + (kdis) \times (NF\kappa B:E2F1)(t) \times I\kappa B\alpha(t)} \\
{- ka3e \times (I\kappa B\alpha:NF\kappa B)(t) \times E2F4(t) + kd3e \times (E2F4:I\kappa B\alpha:NF\kappa B)(t)} \\
{+ c4x \times (E2F4:I\kappa B\alpha:NF\kappa B)(t)} \\
\end{array}\text{\textbackslash eqno}{(17)}$\
$\begin{array}{l}
{\frac{d}{dt}(nI\kappa B\alpha:nNF\kappa B)(t) = ka1a \times nI\kappa B\alpha(t) \times nNF\kappa B(t) - kd1a \times (nI\kappa B\alpha:nNF\kappa B)(t)} \\
{- ke2a \times kv \times (nI\kappa B\alpha:nNF\kappa B)(t) + kdis \times (nNF\kappa B:nE2F1)(t) \times nI\kappa B\alpha(t)} \\
\end{array}\text{\textbackslash eqno}{(18)}$\
$\begin{array}{l}
{\frac{d}{dt}tE2F4(t) = + clx \times \frac{nE2F1^{h}(t)}{nE2F1^{h}(t) + k^{h}} - c3x \times tE2F4(t)} \\
\end{array}\text{\textbackslash eqno}{(19)}$\
$\begin{array}{l}
{\frac{d}{dt}E2F4(t) = c2x \times tE2F4(t) - c4x \times E2F4(t) - ka3e \times NF\kappa B(t) \times E2F4(t)} \\
{+ kd3e \times (E2F4:NF\kappa B)(t) - ka3e \times E2F4(t) \times (I\kappa B\alpha:NF\kappa B)(t)} \\
{+ kd3e \times (E2F4:I\kappa B\alpha:NFkB)(t)} \\
\end{array}\text{\textbackslash eqno}{(20)}$\
$\begin{array}{l}
{\frac{d}{dt}(E2F4:NF\kappa B)(t) = ka3e \times NF\kappa B(t) \times E2F4(t) - kd3e \times (E2F4:NF\kappa B)(t)} \\
{- c4x \times (E2F4:NF\kappa B)(t) + c5a \times (E2F4:I\kappa B\alpha:NF\kappa B)(t)} \\
{- ka3e \times (NF\kappa B:E2F4)(t) \times I\kappa B\alpha(t) + kd3e \times (E2F4I\kappa B\alpha NF\kappa B)(t)} \\
\end{array}\text{\textbackslash eqno}{(21)}$\
$\begin{array}{l}
{\frac{d}{dt}(E2F4:I\kappa B\alpha:NF\kappa B)(t) = + ka3e \times (I\kappa B\alpha:NF\kappa B)(t) \times E2F4(t)} \\
{- kd3e \times (E2F4:I\kappa B\alpha:NF\kappa B)(t) - c5a \times (E2F4:I\kappa B\alpha:NF\kappa B)(t) +} \\
{ka3e \times (NF\kappa B:E2F4)(t) \times I\kappa B\alpha(t) - kd3e \times (E2F4:I\kappa B\alpha:NF\kappa B)(t)} \\
{- c4x \times (E2F4:I\kappa B\alpha:NF\kappa B)(t)} \\
\end{array}\text{\textbackslash eqno}{(22)}$\
10.7554/eLife.10473.029Appendix 1---table 3.Model reactions and associated parameters.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.029](10.7554/eLife.10473.029)ReactionSymbolValueReferences*Spatial parameters*Total cell volumetv2700 µm^3^MeasuredC:N ratiokv3.3MeasuredConversion to nuclear volumenv×(kv+1)-Conversion to cytoplasmic volumecv×(1/kv+1)-*Initial concentration*Total NF-κBNF0.08 µMInitialized as cytoplasmic IκBα·NF-κBTotal IKK-0.08 µMInitialized as IKKn*Complex formation & dissociation*IκBα + NF-κB → IκBα·NF-κB\
nIκBα + nNF-κB → nIκBα·NF-κBka1a0.5 µM^-1^s^-1^([@bib30])IκBα·NF-κB → IκBα + NF-κB\
nIκBα·nNF-κB → nIκBα + nNF-κBkd1a0.0005 s^-1^([@bib30])NF-κB + E2F (1 or 4) → NF-κB·E2F\
nNF-κB + nE2F → nNF-κB·nE2Fka2e0.5 µM^-1^s^-1^fitted, same as IκBα + NF-κBNF-κB·E2F → NF-κB + E2F\
nNF-κB·nE2F → nNF-κB + nE2Fkd2e0.0005 s^-1^fitted, same as IκBα + NF-κBNF-κB·E2F1 + IκBα→ IκBα·NF-κB + E2F1\
nNF-κB·nE2F1 + nIκBα → nIκBα·NF-κB + nE2F1kdis0.001 s^-1^fitted*Transport*NF-κB → nNF-κBki10.0026 s^-1^Measured fitting range: *Average* 0.0026 *±* 0.0018*s^-1^*nNF-κB → NF-κBke10.000052 s^-1^*ki1*/50 ([@bib13])E2F1→ nE2F1kie0.0026 s^-1^fitted, same as NF-κBnE2F1 → E2F1kee0.000052 s^-1^fitted, same as NF-κBIκBα → nIκBαki3a0.00067 s^-1^Measured fitting range:\
Average 0.00043 ± 0.00024 s^-1^nIκBα → IκBαke3a0.000335 s^-1^*ki3a*/2 ([@bib13])nIκBα·nNF-κB → IκBα·NF-κBke2a0.01 s^-1^FittedNF-κB·E2F1 → nNF-κB·nE2F1kine0.0026 s^-1^fitted, same as NF-κBnNF-κB·nE2F1 → NF-κB·E2F1kene0.000052 s^-1^fitted, same as NF-κB*Protein synthesis & degradation*nNF-κB → nNF-κB + tIκBα\
Order of hill function, h=2\
Half-max constant, k=0.065^h^(fitted)c1a1.4×10^-7^\
 µM^-1^s^-1^Fitted (constrained):\
1.07×10^-7^ -- 8.2×10^-7^µM^-1^s^-1^ ([@bib22]);\
([@bib15])tIκBα→ tIκBα + IκBαc2a0.5 s^-1^([@bib42])NF-κB·IκBα→ NF-κBc5a0.000022 s^-1^([@bib51];\
[@bib46])nNF-κB·nIκBα→ nNF-κB-0 s^-1^Assumed ([@bib49];\
[@bib46])nNF-κB → nNF-κB + tA20\
Order of hill function, h=2 Half-max constant, k=0.065^h^c11.4×10^-7 ^\
µM^-1^s^-1^Assumed to be the same as IκBαnE2F1 → nE2F1 + tE2F4\
Order of hill function, h=2 Half-max constant, k=0.065^h^c1x9.8×10^-7^\
µM^-1^s^-1^FittedtA20→ tA20 + A20c20.5 s^-1^-tE2F-4→ tE2F-4 + E2F4c2x0.5 s^-1^-tIκBα→ Sinkc3a0.0003 s^-1^Fitted (constrained): 0.00077-0.00029 s^-1^\
([@bib12])tA20→ Sinkc30.00048 s^-1^Fitted, constrained \>tIκBα\
turnover ([@bib5])tE2F4→ Sinkc3x0.00048 s^-1^FittedIκBα→ Sinkc4a0.0005 s^-1^Fitted (constrained): 0.000105 -- 0.002 s^-1^\
([@bib51]; [@bib49];\
[@bib46])A20 → Sinkc40.0045 s^-1^FittedE2F4 → Sinkc4x0.00016 s^-1^FittedE2F1 → Sinkc6e0.00016 s^-1^FittednE2F1 → Sinkc7e0.00016 s^-1^FittedNF-κB·E2F1 → Sinkc8ne0.00016 s^-1^FittednNF-κB·nE2F1 → Sinkc9ne0.00016 s^-1^Fitted*TNFα stimulation*TNFαTR1/0on/off ([@bib40])*IKK parameters*IKKn → IKKaka0.004 s^-1^Fitted, as aboveIKKa → IKKiki0.003 s^-1^Fitted, as aboveIKKi → IKKnkp0.0006 s^-1^FittedA20 inhibition rate constantkbA200.0018Fitted, scales *kp* dependent on\
receptor state *kbA20×TR*IKKa + IκBα → pIκBαkc1a0.074 s^-1^Assumed (0.037×2) ([@bib27])IKKa + IκBα·NF-κB → pIκBα·NF-κBkc2a0.37 s^-1^Assumed (0.037×5×2)\
([@bib27];\
[@bib80])pIκBα → Sinkkt1a0.1 s^-1^FittedpIκBα·NF-κB → NF-κBkt2a0.1 s^-1^Fitted10.7554/eLife.10473.030Appendix 1---table 4.Simulation protocols used throughout the manuscript. TNFα stimulation is invoked via TR=0/1. E2F refers to levels of \'transfection\' (in μM). E2F4 off/on refers to whether its transcription is switched on or off.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.030](10.7554/eLife.10473.030)FigureModel conditions3ETR=0, E2F1= (0.05, 0.1, 0.15), E2F4 off4ATR=1, E2F1 = 0.1, E2F4 off4CTR=1, E2F1 = 0.1, E2F4 on4I (G1, G2)TR=1, E2F1= 0, E2F4 on (but unaffected)4I (G1/S)TR=1, E2F1 = 0.2, E2F4 on4I (S)TR=1, NFkBIkBa = 0.1, E2F1 = 0, E2F4= 0.110.7554/eLife.10473.031Appendix 1---figure 6.Simulations from the NF-κB:E2F model.Blue lines represent *E2F1*= 0, TR= 1. Black lines represent *E2F1*= *NFkB*= 0.1 and TR=0. Red lines represent *E2F1*= *NFkB*= 0.1 and TR=1.**DOI:** [http://dx.doi.org/10.7554/eLife.10473.031](10.7554/eLife.10473.031)

Section C: Generation of recombinant Bacterial Artificial Chromosome (BAC) {#s33}
==========================================================================

Bacterial artificial chromosomes (BACs) containing the human E2F-1 gene with 98.7 kb 5′ flanking DNA, 45.5 kb 3′ flanking DNA (RP11-246G11) or the human RelA gene with 82 kb 5′ and 15 kb 3′ flanking DNA (CTD 2116H8) were identified using genome browser (<http://genome.ucsc.edu>) and obtained from Invitrogen/Life technologies. The targeting strategy to create BACs expressing fusion protein products were based on the seamless recombineering technology developed by [@bib71], with minor modifications. Chimeric primers to amplify the GalK gene tagged with homology arms corresponding to the 50--80 bp immediately up and downstream of the stop codon of the gene were used to generate the H-GalK-H recombination cassette for primary targeting. The length of GalK specific portion of the primers was extended to increase Tm and thus the efficiency of the PCR using a two-step PCR method (Phusion high fidelity enzyme, Finnzymes; primer sequences below). The second targeting cassette was generated using chimeric primers with the same homology arms but amplifying the desired fluorescent fusion protein, H-Venus-H for E2F1 or DsRedxp for RelA. Recombination and selection was carried out according to routine protocols ([@bib71]) available at <http://recombineering.ncifcrf.gov>. Clone screening was performed by pulsed field gel electrophoresis, Southern blots and sequencing to confirm in-frame C-terminal insertion of the reporter gene.

Primers used (italics denote homology arm sequence):

E2F1-GalKF

*TCAGAGACCTCTTCGACTGTGACTTTGGGGACCTCACCCCCCTGGATTTC*CCTGTTGACAATTAATCATCGGCATAGTATATCG

E2F1-Galk R

*TGCAGAGACAAGGTGAGCATCTCTGGAAACCCTGGTCCCTCCAAGCCCTG*TCAGCACTGTCCTGCTCCTTGTGA

E2F1-Venus F

*CCACTTCGGCCTCGAGGAGGGCGAGGGCATCAGAGACCTCTTCGACTGTGACTTTGGGGACCTCACCCCCCTGGATTTC*ATGGTGAGCAAGGGCGAGGAG

E2F1-Venus R

*CGGCCAGGGACAGGGGGCTCCAGGGCTGCAGAGACAAGGTGAGCATCTCTGGAAACCCTGGTCCCTCCAAGCCCTG*CTACTTGTACAGCTCGTCCATGCC

RelA-GalKF

*ATGAAGACTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAGATCAGCTCC*CCTGTTGACAATTAATCATCGGCATAGTATATCG

RelA-Galk R

*CAGAATCCGTAAGTGCTTTTGGAGGGCTTCAATCCCCTGCAACCCAGTGCTCTGGGGAGGGCAGGCGTCACCCCC*TCAGCACTGTCCTGCTCCTTGTGA

RelA-DsRedxp F

*ATGAAGACTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAGATCAGCTCC*ATGGCCTCCTCCGAGGACGTC

RelA-DsRedxp

R*CAGAATCCGTAAGTGCTTTTGGAGGGCTTCAATCCCCTGCAACCCAGTGCTCTGGGGAGGGCAGGCGTCACCCCCC*TACAGGAACAGGTGGTGGCG

The BAC were initially transiently transfected into HeLa cells using ExGen500 transfection reagent (Fermentas, UK) to confirm fluorescent protein function.

BAC stable cell line generation {#s34}
===============================

To generate stable cell lines it was necessary to retrofit the BAC with an appropriate mammalian selection marker. Retrofitting constructs that could universally be applied to any BAC were developed. As the same parent BAC vector construct, pBAC108L, was used to derive the most common BAC vectors, pe3.6 (from the Roslin Park institute library) and the pBeloBAC vector (from the California Institute of Technology) approximately 6kb of the vectors had perfect sequence homology. Within this region the chloramphenicol resistance gene was identified as a suitable target for replacement with a new selection marker as this would not disrupt important bacterial sequences. Restriction site-tagged homology arms 300-400 bp in length were amplified from the BAC sequence using the primers (underlined indicates enzyme site):

5'H *Kpn*I F tgtcaa[GGTACC]{.ul}GGCAGCCACATCCAG,

5'H *Eco*RI R ggtgcc[GAATTC]{.ul}TCAACGTCTCATTTTCGC,

3'H *Bam*HI F aatggg[GGATCC]{.ul}TGGACAACTTCTTCGCC,

3'H *Sac*II R aatggg[CCGCGG]{.ul}GCCGTCGACCAATTCTC

and cloned using the appropriate enzymes into the multiple cloning sites of pL451 ([@bib43]). This resulted in a recombination cassette containing H-pGK-pEM7-Kan/Neo-H. Retrofitting was performed in the same SW102 strain hosting the BAC by heat induction of the bacteria for recombination, transforming with the cassette and plating on LB containing Kanamycin (25 µg/ml). Clones were screened by PFGE and \>90% recombination efficiency was observed.

Stable BAC transfection {#s35}
=======================

BAC DNA was prepared by maxiprep (BAC100 Nucleobond kit, Macherey-Nagel, Germany) and 1 µg or 3 µg used to transfect 10^6^ cells in a 10 cm dish using ExGen500 transfection reagent. Media was changed 3 days post transfection and supplemented with 500 µg/ml G418. Media + antibiotic were refreshed every 3--4 days. Colonies formed 2--3 weeks after culturing in selection containing media were ring cloned into individual wells of a 48 well plate and sequentially scaled up to large culture vessels as necessary.

A HeLa cell line stably expressing the E2F-1-venus bacterial artificial chromosome (BAC), was transiently transfected with a FUCCI marker for G1-phase. Shows two consecutive cycles of HeLa cell division for a representative cell ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Parent and daughter cells showed cycles of E2F-1 expression, with a peak timing consistent with late G1-phase.

Section D: BAC characterisation {#s36}
===============================

![Cell Cycle length of Clonal HeLa BAC population.\
(**A**) Analysis of cell cycle duration in populations of dual BAC stable cell line (C1-1) with wild type HeLa cells. (**B**) Analysis of the effects of TNFα treatment in C1-1 and WT HeLa cells.\
**DOI:** [http://dx.doi.org/10.7554/eLife.10473.032](10.7554/eLife.10473.032)](elife-10473-app1-fig7){#fig15}

Section E: Controls for FCCS {#s37}
============================

Physical interaction between RelA and IκBα was confirmed using FCCS in SK-N-AS cells co-expressing RelA-DsRedxp and IκBα-EGFP. FCS exploits fluorescence-intensity fluctuations caused by low numbers of diffusing labelled particles in a diffraction limited confocal volume of light to analyse their concentration and mobility ([@bib64]). Fluctuations are recorded as function of time and then statistically analysed by autocorrelation analysis. In its dual-colour variant, FCCS, two spectrally distinct fluorophores (such as red and green) are used and the cross-correlation amplitude in conjunction with the auto-correlation amplitudes provides information on molecular binding as well as dynamic co-localisation. In contrast to FRET, FCCS does not depend on the very close proximity of the interacting fluorescent labels.10.7554/eLife.10473.033Appendix 1---figure 8.FCCS control.FCCS assays between transiently transfected RelA-dsRedxp and IκBα-EGFP (red line) and Empty-DsRedxp and Empty-EGFP (blue line) in single live SK-N-AS cells (+/- s.e.m based on 10 measurements in each of 10+ cells per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.033](10.7554/eLife.10473.033)

Auto-correlation analysis was conducted to show comparable noise between measurements and between controls for RelA/E2F-1 FCCS data10.7554/eLife.10473.034Appendix 1---figure 9.FCCS autocorrelation analysis.Autocorrelation lines for RelA/IkBα, RelA/E2F-1 and RelA/E2F-4 FCCS studies in single live SK-N-AS cells (+/- s.e.m based on 10 measurements in each of 10+ cells per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.10473.034](10.7554/eLife.10473.034)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Dynamic NF-κB and E2F interactions control the priority and timing of inflammatory signalling and cell proliferation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Aviv Regev as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

Ankers et al. examine the impact of the cell cycle on cellular variability during NF-κB response to TNFα. Using a combination of fluorescent microscopy, biochemical assays, and a computation model, they show cell cycle dependent variability in NF-κB response, which is a result of physical interactions between NF-κB with E2F-1 and E2F-4 proteins.

Specifically, using transient overexpression of fluorescent fusion proteins combined with cell cycle synchronization, the authors show that the NF-κB response to TNF is attenuated in S-phase, while pathway activation before G1/S transition prolongs the cell cycle. The refractoriness of cells in S-phase led the authors to test an E2F-1 target gene E2F-4 for a role in mediating the S phase-specific inhibitory interaction of RelA with E2F-4. The authors found that interplay between cell cycle and NF-κB response is based on physical interactions of RelA with the transcription factors E2F-1 and -4, as shown by CO-IP, FRET and FCCS. While E2F-1 leads to prolonged nuclear accumulation of RelA by competing with IκBα binding and preventing expression of the feedback regulator, E2F-4 binding leads to cytoplasmic localization of RelA. Finally, the authors validate their results using fusion proteins expressed at physiological levels through a BAC expression system.

The reported findings are highly significant for understanding the interplay between cellular signalling and cell cycle control and are potentially of interest for a broad audience. However, the reviewers have outlined concerns that needed to be addressed to strengthen the stated conclusions of the manuscript.

Essential revisions:

1\) The authors\' use of transiently transfected RelA, in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} weakens the data by two factors: a) RelA abundance is bound to be very variable from cell to cell and b) variable RelA abundance could affect cell cycle timing yet the cell cycle mapping using time since mitosis is based on calibration done in other cells. The data from the BAC stable cell line introduced later in the paper is much stronger. We suggest that the authors either acquire data for a greater cell number with this cell line and replace data in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} with the new data, or alternatively, integrate data from the BAC cell lines with that of the transiently transfected cell line in the early figures of the paper so that the first segment of the is strengthened.

2\) Overall, in the data presented in this manuscript, the oscillations in nuclear RelA fusion protein amount seem very damped with little or no second peaks. Importantly, this is observed not only for HeLa (which showed more damped oscillations in their original 2004 Science paper) but also for SK-N cells (which showed more robust oscillations in the 2004 paper). Although the study focuses on a shorter time window encompassing mostly the first peak, the apparent lack of robust oscillations will be puzzling to many readers familiar with the authors\' previous work and warrants some explanation.

3\) Some of the experiments require more upfront controls, validations or stronger explanations:

A\) The authors should show by immunoblot that synchronization of HeLa cells with a double thymidine block of DNA synthesis does not significantly change the abundance of tagged RelA.

B\) How does overexpression of E2F-1 and E2F-4 impact cell cycle? Does inducing NF-κB with TNF during E2F-1 overexpression have a negative impact on cells that are in S-phase and that normally would not respond during this time?

C\) The CO-IPs in 5D and 7B would benefit from showing a RelA pull down in each of the other phases as a comparison to the phase in question.

D\) In 5B and 7D, the fluorescence changes for YFP and CFP are unexpectedly symmetrical after photobleaching: Because the inter-molecular FRET ratio to CFP is likely only a few percent, how can the increase in CFP be of the same magnitude as the decrease in YFP? Related, why is efficiency of YFP bleaching so different between these two experiments? A better explanation of the experiment and quantification of the results would really help, as would bringing the controls in Section E of the supplements to the main figures (or a linked supplement), allowing the readers to more easily compare results obtained with photobleached non-interacting probes.

4\) The consequence of the E2F-1 -- RelA interaction is unclear. Overexpression of E2F-1 inhibits RelA target gene expression despite inducing its nuclear accumulation ([Figure 4](#fig4){ref-type="fig"}). Is this caused by loss of RelA-binding to DNA or is the recruitment of the transcriptional machinery prevented? As mentioned in the Discussion, previous studies reported that both proteins are binding to the same promoters and co-activate genes (e.g. Lim et al., Mol Cell 2007). How does this fit in with the data in this manuscript and the interpretation? The authors hypothesize that loss of feedback (IκBα) expression causes the stronger NF-κB response at G1-S. While additional experiments may be outside of the scope of the study, overall this interpretation is not intuitive and therefore it is important for the authors to both clarify their interpretation and how it is supported (or not) by the different pieces of evidence.

5\) The authors show that binding to E2F-4 keeps RelA in the cytoplasm, however, no data at this time elucidates whether E2F-4 competes for IκBα binding or whether a tertiary complex formed. Furthermore, the immunoblot data shown in [Figure 6E](#fig6){ref-type="fig"} is not definitive enough to demonstrate that the effect of E2F-4 is through the stabilization of IκBα, and even so, this interpretation contradicts the final model in [Figure 9](#fig9){ref-type="fig"} which is confusing to readers. While further characterization of these interactions may be outside of the scope of the current study, the model in [Figure 9](#fig9){ref-type="fig"} should be consistent will all the data, and it should be made clear that the role of E2F-4 is speculative. Furthermore, it would be helpful to briefly mention in the main text what terms are included in the refined model for E2F-4: binding to RelA and/or IκBα? This way the readers would appreciate which interactions are necessary to explain the data without delving into the model descriptions in the Supplementary section.

6\) The authors show that NF-κB activation at the G1/S boundary induces elongation of the cell cycle. However, it remains unclear what the molecular mechanisms are, and the effects are subtle. The reviewers therefore suggest that authors put overall the greatest focus of the manuscript on the modulation of NF-κB signalling by E2F proteins.

7\) As there is existing literature regarding the interaction of NF-κB, E2Fs and the cell cycle -- in 2002, Tanaka et al. showed reduced NF-κB activation in S-phase compared to G1 and G2, although upon a different stimulus, and could connect this to the state of E2F-1 protein (Tanaka et al. Mol Cell 2002) -- the authors should discuss and cite these results.

10.7554/eLife.10473.038

Author response

Essential revisions:

1\) The authors\' use of transiently transfected RelA, in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} weakens the data by two factors: a) RelA abundance is bound to be very variable from cell to cell and b) variable RelA abundance could affect cell cycle timing yet the cell cycle mapping using time since mitosis is based on calibration done in other cells. The data from the BAC stable cell line introduced later in the paper is much stronger. We suggest that the authors either acquire data for a greater cell number with this cell line and replace data in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} with the new data, or alternatively, integrate data from the BAC cell lines with that of the transiently transfected cell line in the early figures of the paper so that the first segment of the is strengthened.

The reviewers suggested that [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} be either replaced or integrated with data from the BAC cell line. We feel that the introduction of the BAC cell line early in the paper would adversely affect the flow of the manuscript, since transient transfection is also used in [Figures 4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}. The reviewers nevertheless suggest that data from the BAC stable cell line is much stronger than the transiently transfected RelA data and that we should include more data from this cell line. We agree that the BAC stable cell line is a significant step forward and strengthens interpretation of the transient transfection data. We have now generated and analysed the data from a substantial number of cells from this cell line. These new data map the level of NF-κB translocation in relation to cell cycle phase for a substantial number of cells. (See new [Figure 8](#fig8){ref-type="fig"}). This new data set also presented the opportunity for the first time to map the corresponding E2F1-Venus levels across a population of cells. These data are shown in a new [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}. The trace of E2F expression at different cell cycle times is also used to help illustrate the new statistical analysis of the complete RelA translocation data set, which is shown in [Figure 8B](#fig8){ref-type="fig"}. We were able to infer on a cell-by-cell basis the cell cycle phase (G1, S-phase, G2) for each cell at the onset of TNFα stimulation. This was achieved by using the timing of the peak of E2F-1 expression to identify the onset of S-phase. This approach was validated through direct comparison of the E2F-1 trace in single E2F-1-Venus BAC stable cells transfected with FUCCI G1 phase marker construct (now [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}).

Rather than superseding the transient transfection data, we therefore believe that the data from analysis of the double BAC cell line is entirely complementary with the earlier presentation of the transient transfection data. This order of presentation of the experiments provides a more logical experimental framework in which the BAC cell data can be characterised and interpreted. We hope the reviewers will agree that the new [Figure 8](#fig8){ref-type="fig"} adds a substantial and important new data set that helps to illustrate and support the ordering of the presentation of the data and the optimal development of the evidence for the main conclusions of this paper.

*2) Overall, in the data presented in this manuscript, the oscillations in nuclear RelA fusion protein amount seem very damped with little or no second peaks. Importantly, this is observed not only for HeLa (which showed more damped oscillations in their original 2004 Science paper) but also for SK-N cells (which showed more robust oscillations in the 2004 paper). Although the study focuses on a shorter time window encompassing mostly the first peak, the apparent lack of robust oscillations will be puzzling to many readers familiar with the authors\' previous work and warrants some explanation.* The impression that there are more damped or fewer oscillations in nuclear RelA is due (as the reviewers note) to the shorter time window of the experiments. We have now included an additional Figure that illustrates the traces over a longer timecourse ([Appendix 1---figure 1](#fig10){ref-type="fig"}). We hope that this will remove the impression that there is a discrepancy in these data.

3\) Some of the experiments require more upfront controls, validations or stronger explanations:

A\) The authors should show by immunoblot that synchronization of HeLa cells with a double thymidine block of DNA synthesis does not significantly change the abundance of tagged RelA.

We show that a double thymidine block has no effect on RelA-dsRedxp levels in the C1-1 double BAC stable cell line. This blot is now included in the Appendix ( [Appendix 1---figure 3](#fig12){ref-type="fig"}).

*B) How does overexpression of E2F-1 and E2F-4 impact cell cycle? Does inducing NF-κB with TNF during E2F-1 overexpression have a negative impact on cells that are in S-phase and that normally would not respond during this time?* Transient transfection of E2F-1 plasmids with a CMV promoter caused apoptosis and cells were rescued by co-transfection with Rel-A. It was unclear if apoptosis was caused by overexpression or out of context expression of E2F-1. In contrast E2F-4 transient transfection did not cause apoptosis and cells were seen to divide as normal. A key attribute of the dual BAC stable cell line was that (as shown in ) the cells express low levels of the E2F-1-Venus fusion protein that are much lower than the endogenous E2F-1 levels. Therefore, the E2F-1 fluorescent protein expression in this context appears to not perturb the normal cell cycle. It must be noted that throughout the virtual synchronisation experiments we analysed data from cells through two successive cell divisions.

*C) The CO-IPs in 5D and 7B would benefit from showing a RelA pull down in each of the other phases as a comparison to the phase in question.* We fully understand this suggestion. However, the CO-IPs were difficult to perform and gave only a low signal. This appeared to be in agreement with the FRET and FCS data which suggested a relatively low affinity interaction between E2F-1 and E2F-4 and RelA. In our experiments we were only able to see any indication of an interaction by CO-IP in cells that had been synchronised in late G1/S (i.e. at the peak of E2F-1 expression). We could not see a significant interaction in asynchronous cells. Under these circumstances showing a negative CO-IP blot at other cell cycle stages seems uninformative. In this context it should be noted that this is not a new piece of data, since other groups had already shown this interaction by pull-down in other cell types (see papers by Lim et al., Garber et al., and Tanaka et al., cited in the manuscript).

*D) In 5B and 7D, the fluorescence changes for YFP and CFP are unexpectedly symmetrical after photobleaching: Because the inter-molecular FRET ratio to CFP is likely only a few percent, how can the increase in CFP be of the same magnitude as the decrease in YFP? Related, why is efficiency of YFP bleaching so different between these two experiments? A better explanation of the experiment and quantification of the results would really help, as would bringing the controls in Section E of the supplements to the main figures (or a linked supplement), allowing the readers to more easily compare results obtained with photobleached non-interacting probes.* The reviewer notes that changes in donor fluorescence appear to be beyond the physical limit of non-radiative energy transfer between CFP and YFP. However, within this manuscript, FRET measurements following acceptor photobleaching were purely qualitative measures of interaction, used to supplement FCCS and CO-IP measurements. Data were collected using λ scans and linear unmixing using reference spectra and no efficiency of interaction was assumed. Measurements were normalised to pre-bleach fluorescence, and the relative change of donor fluorescence was used to qualitatively infer FRET. The manuscript has been amended appropriately and negative controls have been added to [Figure 5](#fig5){ref-type="fig"}.

4\) The consequence of the E2F-1 -- RelA interaction is unclear. Overexpression of E2F-1 inhibits RelA target gene expression despite inducing its nuclear accumulation ([Figure 4](#fig4){ref-type="fig"}). Is this caused by loss of RelA-binding to DNA or is the recruitment of the transcriptional machinery prevented? As mentioned in the Discussion, previous studies reported that both proteins are binding to the same promoters and co-activate genes (e.g. Lim et al., Mol Cell 2007). How does this fit in with the data in this manuscript and the interpretation? The authors hypothesize that loss of feedback (IκBα) expression causes the stronger NF-κB response at G1-S. While additional experiments may be outside of the scope of the study, overall this interpretation is not intuitive and therefore it is important for the authors to both clarify their interpretation and how it is supported (or not) by the different pieces of evidence. The reviewers make a good point here that we had tried to discuss in the manuscript. We do not suggest that E2F-1 acts to sequester RelA in the nucleus through strong binding (see response to point 3 above). While this might be suggested by our experiments in [Figure 4](#fig4){ref-type="fig"}, it must be recognised that these experiments (although informative) are based on expression from a plasmid vector. Instead we suggest that E2F-1 competes with IκBα binding and the RelA-E2F-1 complex can then interact with promoters to differentially modulate transcription.

As shown in [Figure 4](#fig4){ref-type="fig"}, the predominantly cytoplasmic localisation of RelA-dsRedxp when expressed alone was changed to a predominantly nuclear localisation in cells co-expressing RelA-dsRedxp and EGFP-E2F-1. In addition however we also find that the steady-state cytoplasmic localisation of RelA is restored in cells expressing IkBα-AmCyan, EGFP-E2F-1 and RelA-dsRedxp (new panel now added to [Figure 4E](#fig4){ref-type="fig"}). These data suggest the hypothesis that IkBα and E2F-1 compete for the same binding site on RelA, with IkBα perhaps having the higher affinity. We therefore suggest that at G1/S the high E2F1 levels result in formation of a transcription factor complex between RelA and E2F-1 in the nucleus of TNFα stimulated cells. This might activate some genes and repress others. However, our data in [Figure 4A and B](#fig4){ref-type="fig"} suggest that the presence of E2F-1 results in repression of NF-κB-dependent IκBα expression. As a result, we suggest that the longer and often larger peak of nuclear RelA in G1/S simulated cells may be due to a delay in the new round of IκBα expression and synthesis. The mathematical model fully encapsulates this hypothesis. We have amended the Discussion to try to make these points clearer.

5\) The authors show that binding to E2F-4 keeps RelA in the cytoplasm, however, no data at this time elucidates whether E2F-4 competes for IκBα binding or whether a tertiary complex formed. Furthermore, the immunoblot data shown in [Figure 6E](#fig6){ref-type="fig"} is not definitive enough to demonstrate that the effect of E2F-4 is through the stabilization of IκBα, and even so, this interpretation contradicts the final model in [Figure 9](#fig9){ref-type="fig"} which is confusing to readers. While further characterization of these interactions may be outside of the scope of the current study, the model in [Figure 9](#fig9){ref-type="fig"} should be consistent will all the data, and it should be made clear that the role of E2F-4 is speculative. Furthermore, it would be helpful to briefly mention in the main text what terms are included in the refined model for E2F-4: binding to RelA and/or IκBα? This way the readers would appreciate which interactions are necessary to explain the data without delving into the model descriptions in the Supplementary section. Our data proposes a clear mechanism for the functional action of E2F-1. However, the mechanism of E2F-4 remains less clear. One issue that must be recognised is that these are just two members of a family of E2F proteins. It has been outside the feasible scope of the present study to characterise them all. One surprising characteristic of the E2F-4 transcription factor is that its predominant localisation (at least in some cell types) is in the cytoplasm. Presumably a subset of the protein is also in the nucleus where it acts as a transcription factor. In the response to the question about E2F-1 above we have added to the paper data that supports the hypothesis that E2F-1 may compete with IκBα for binding to RelA. This was possible due to the predominant nuclear localisation of E2F-1. However due to its cytoplasmic localisation a similar experiment is not possible for E2F-4. In FCS and FRET experiments we found no evidence for an interaction between either E2F-1 and IκBα or E2F-4 and IκBα (data not shown). Therefore, it seems plausible, as suggested in the comment by the reviewers, that E2F-4 may also compete for IκBα binding. However in the absence of an E2F-4 BAC cell line (which was beyond the scope of this study) it is not possible to provide any clear evidence for the mechanism of E2F-4 inhibition. The mathematical model (and the diagram in [Figure 9](#fig9){ref-type="fig"}) for simplicity currently has E2F-4 binding to the RelA-IκBα complex. We have endeavoured to include more discussion in the paper that makes this issue clearer, so that readers will understand the extent of our current evidence and claims.

The representation in [Figure 9](#fig9){ref-type="fig"} is entirely in agreement with our data and our model and is currently the simplest representation of the system, given the uncertainties discussed above. We had included a phosphorylation on the RelA molecule in the diagram that was a distraction and this has now been removed. We hope that this may make the diagram clearer to the readers.

*6) The authors show that NF-κB activation at the G1/S boundary induces elongation of the cell cycle. However, it remains unclear what the molecular mechanisms are, and the effects are subtle. The reviewers therefore suggest that authors put overall the greatest focus of the manuscript on the modulation of NF-κB signalling by E2F proteins.* In the manuscript, we reported how TNFα treatment results in the elongation of cell cycle. We further noted that this elongation is dependent upon the cell cycle phase with cells treated in late G1 being more susceptible to elongation and cells treated in S-phase showing no difference from the untreated population average. When comparing the results of late G1 to S-phase treated cells, the differences are quite dramatic and statistically significant. Since we also saw high NF-κB response in late G1 and a reduced response in S-phase, we suggested that there is a 2-way interaction between the NF-κB and cell cycle systems. In agreement with the reviewers, we note that this remains a hypothesis and that we do not give a specific mechanism. We believe these data are interesting and are indicative of the potential direct role of NF-κB in mediating cell cycle duration following cytokine stimulation.

Following the reviewers' suggestion we have reworded the corresponding Results section in the manuscript to better clarify our observation. In addition, we have expanded the Discussion to explore possible hypotheses regarding this observation and now include mention of other possible downstream cell cycle targets of NF-κB. We have also amended the final sentence of the Abstract so that the main focus is on cell cycle control of NF-κB responses.

7\) As there is existing literature regarding the interaction of NF-κB, E2Fs and the cell cycle -- in 2002, Tanaka et al. showed reduced NF-κB activation in S-phase compared to G1 and G2, although upon a different stimulus, and could connect this to the state of E2F-1 protein (Tanaka et al. Mol Cell 2002) -- the author should discuss and cite these results.

We have now cited this paper and have included discussion of its results.

[^1]: These authors contributed equally to this work.
